



Disrupted neuronal trafficking in amyotrophic lateral sclerosis

Katja Burk^{1,2} · R. Jeroen Pasterkamp³

Received: 12 October 2018 / Revised: 19 January 2019 / Accepted: 19 January 2019 / Published online: 5 February 2019
© The Author(s) 2019

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive, adult-onset neurodegenerative disease caused by degeneration of motor neurons in the brain and spinal cord leading to muscle weakness. Median survival after symptom onset in patients is 3–5 years and no effective therapies are available to treat or cure ALS. Therefore, further insight is needed into the molecular and cellular mechanisms that cause motor neuron degeneration and ALS. Different ALS disease mechanisms have been identified and recent evidence supports a prominent role for defects in intracellular transport. Several different ALS-causing gene mutations (e.g., in *FUS*, *TDP-43*, or *C9ORF72*) have been linked to defects in neuronal trafficking and a picture is emerging on how these defects may trigger disease. This review summarizes and discusses these recent findings. An overview of how endosomal and receptor trafficking are affected in ALS is followed by a description on dysregulated autophagy and ER/Golgi trafficking. Finally, changes in axonal transport and nucleocytoplasmic transport are discussed. Further insight into intracellular trafficking defects in ALS will deepen our understanding of ALS pathogenesis and will provide novel avenues for therapeutic intervention.

Keywords Amyotrophic lateral sclerosis · Motor neuron · Trafficking · Cytoskeleton · Rab

Introduction

Amyotrophic lateral sclerosis (ALS) is a fatal disease characterized by the degeneration of upper and lower motor neurons causing muscle denervation. In the majority of patients, the cause of the disease is unknown and these cases are referred to as sporadic ALS (SALS) cases. In 5–10% of cases, there is a family history of ALS (FALS) [142]. The prevalence of ALS in most countries is around five cases per 100,000 people [2] with a median age of onset of SALS of 65 years, while, for genetically heterogeneous populations,

onset is about 10 years earlier [44]. As disease progresses, corticospinal motor neurons, projecting from the motor cortex to the brainstem and spinal cord, and bulbar and spinal motor neurons, projecting to skeletal muscles, degenerate. Consequently, muscles innervated by these neurons deteriorate and patients usually die from respiratory failure within 3–5 years after symptom onset [44].

Despite the general notion that ALS is a neuromuscular disease, in many patients, the CNS is affected more generally. Between 5 and 15% of patients with ALS also have frontotemporal dementia (FTD), while up to 50% of ALS patients display cognitive or behavioral changes within the spectrum of FTD [44]. The mechanisms that cause motor neuron degeneration and ALS remain incompletely understood. Mutations in > 30 genes have been linked to FALS, and on basis of the functions of these genes, different disease pathways have been proposed and investigated. For example, in about 60–80% of patients with FALS, the most common mutations are in *C9ORF72* (40%), *SOD1* (20%), *FUS* (1–5%), and *TARBDP* (1–5%) [142]. These genetic defects suggest changes in molecular pathways controlling; for example, RNA biology, protein turnover, and axonal transport [144].

✉ Katja Burk
kburk@gwdg.de

✉ R. Jeroen Pasterkamp
R.J.Pasterkamp@umcutrecht.nl

¹ Department of Neurologie, Universitätsmedizin Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany

² Center for Biostructural Imaging of Neurodegeneration, Von-Siebold-Str. 3A, 37075 Göttingen, Germany

³ Department of Translational Neuroscience, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Universiteitsweg 100, 3584 CG Utrecht, The Netherlands

Interestingly, an increasing number of recent studies report defects in intracellular trafficking in ALS, but much remains unclear about the role of altered trafficking in motor neuron degeneration. For example, what is the precise effect of gene mutations on protein function and distribution? Do different affected proteins control separate steps of intracellular trafficking or does their function converge onto common pathways? In this review, we discuss different intracellular trafficking processes that have been linked to the pathogenesis of ALS. These range from endosomal trafficking and autophagy to axonal and nucleocytoplasmic transport. We discuss how these processes, and the proteins that control them, are altered in ALS and provide directions for future research.

Disrupted receptor and endosomal trafficking

An increasing number of trafficking defects are being linked to the pathogenesis of ALS. In this section, we will discuss the evidence for changes in receptor and endosomal trafficking. In this and each of the following sections, the effects of individual ALS-associated genes are highlighted first, followed by a discussion on how these individual defects may be interconnected. When trafficking defects have been covered extensively in recent review articles, we will refer to these reviews and focus on the most significant findings.

One of the most impactful recent genetic findings in ALS is the discovery of an ALS-FTD causative mutation in Chromosome 9 open reading frame 72 (*C9ORF72*) in the form of a GGGGCC hexanucleotide repeat expansion in the first intron of the *C9ORF72* locus (from a typical 5–10 repeats in controls to hundreds or more in patients) [33, 136, 143, 177]. This mutation occurs with high frequency in individuals of European descent but less in other populations [76]. In humans, three alternatively spliced *C9ORF72* transcripts exist, predicted to produce two polypeptide isoforms [33]. Different mechanisms have been proposed through which *C9ORF72* repeat expansions contribute to ALS pathology. First, the hexanucleotide repeat expansion leads to genetic haploinsufficiency by forming stable G-quadruplex structures that disrupt transcription [50]. The repeat expansion may also promote hypermethylation of the locus, thereby further attenuating *C9ORF72* expression [190]. Second, GGGGCC repeat-containing RNA accumulates in nuclear foci [33, 58] which may lead to toxic gain of RNA function through sequestration of RNA-binding proteins [170]. Third, GGGGCC repeat-containing RNA can undergo repeat-associated non-ATG (RAN) translation resulting in the generation of toxic dipeptide repeat (DPR) proteins which accumulate in the brain in disease [118, 119].

The precise mechanism through which hexanucleotide expansions in *C9ORF72* cause motor neuron degeneration is subject of intense study but remains incompletely understood. However, several observations support the idea that surface expression, trafficking, and recycling of cell surface receptors are affected in *C9ORF72* ALS/FTD patient cells. For example, in induced motor neurons (iMNs) from *C9ORF72* ALS/FTD patients, elevated cell surface levels of the NMDA receptor NR1 and the AMPA receptor GluR1 are found on neurites and dendritic spines compared to control iMNs. Furthermore, glutamate receptors accumulate at post-synaptic densities in these neurons [194]. Elevated levels of glutamate receptors may induce hyperexcitability and cell death due to increased glutamate activation (Fig. 1). In line with this idea, activation of Kv7 potassium channels increases the survival of *C9ORF72* patient-derived and *C9ORF72*-deficient iMNs [194]. Another class of transmembrane receptors affected by *C9ORF72* mutations are Mannose-6-phosphate receptors (M6PRs) [194]. In iMNs from patients with *C9ORF72* mutations, M6PRs cluster and move at slower rates as compared to control [194]. Another study shows that M6PRs localize in the cytosol of *C9ORF72* ALS/FTD fibroblasts in contrast to their perinuclear localization in control cells [5]. Given the role of M6PRs in targeting lysosomal enzymes to lysosomes these changes could affect lysosomal degradation (Fig. 1).

Elevated cell surface levels of NMDA and AMPA receptors and defective trafficking of M6PRs in *C9ORF72* patient-derived and *C9ORF72*-deficient iMNs could result from defects in multiple steps of the intracellular trafficking pathway. Interestingly, several studies show that endocytosis and recycling mechanisms are impaired in *C9ORF72* ALS/FTD. For example, decreased expression of Vps26, a component of the retromer complex [22], found in *C9ORF72* ALS/FTD fibroblasts could lead to abnormal endosomal recycling [5]. Furthermore, knockdown of *C9ORF72* in SH-SY5Y cells causes impaired endocytosis of tropomyosin receptor kinase receptor B (TrkB) [47]. In addition, multiple lines of experimental evidence link *C9ORF72* to Rab-GTPases. Rab-GTPases control different steps of the intracellular trafficking pathways including vesicle formation, movement and membrane fusion (for review, see [162, 199]).

Rab-GTPases alternate between two conformational states: the activated guanosine tri-phosphate (GTP)-bound state and the guanosine di-phosphate (GDP)-bound inactive state. Exchange of GDP with GTP is catalyzed by Rab guanine-nucleotide exchange factors (GEFs) that act at specific membranes and facilitate GDP release. In contrast, GAPs (GTPase activating proteins) catalyze GTP hydrolysis to GDP [162, 199]. It has been found that *C9ORF72* contains a DENN-like domain [100, 196] which acts as an Rab-GEF [77]. In addition, *C9ORF72* binds several of the over 60 human Rab-GTPases. To investigate with




Fig. 1 Effects of ALS-associated C9ORF72 repeat expansions. C9ORF72 hexanucleotide repeat expansions lead to C9ORF72 haploinsufficiency, and RNA and dipeptide repeat protein (DPR)-mediated toxic gain of function mechanisms that affect motor neurons (MNs) by deregulating endosomal and receptor trafficking leading to reduced protein degradation and enhanced aggregation, reduced survival, and glutamate toxicity. For several of these defects, it is unknown if they are caused by C9ORF72 loss and/or gain of function phenotypes. Only, for defects where evidence is compelling enough the precise mechanism (C9ORF72 loss or gain of function) is mentioned below. **a** M6P receptors (M6PR) are transported at slower rates and display subcellular mislocalization in C9ORF72 patient-derived induced (i) MNs. Since M6PR contributes to protein degradation by delivering cargo to lysosomes, M6PR mistrafficking may cause reduced protein degradation. **b** In MNs, C9ORF72 localizes to Rab5-positive early endosomes and acts as a Rab-GEF. In iMNs from C9ORF72 ALS

patients and in spinal motor neurons in *Nestin-Cre;C9orf72^{fl/fl}* mice, the number of Lamp1-, 2-, and 3-positive lysosomes is decreased. Together, these data support a model in which C9ORF72 haploinsufficiency inhibits endosomal maturation and consequently induces a decrease in the number of lysosomes and in protein degradation. **c** C9ORF72 patient-derived and C9ORF72 deficient iMNs show hyperexcitability and enhanced cell surface expression of glutamate receptors, which may lead to glutamate toxicity. **d** C9ORF72 loss- and gain-of-function mechanisms may cooperate. Reduced protein degradation as a result of C9ORF72 haploinsufficiency may facilitate the enhanced accumulation of toxic DPRs or other ALS-associated proteins in MNs. **e** Impaired endocytosis of TrkB receptors in C9ORF72 patient-derived MNs negatively affects neuronal survival. This figure was created using Servier Medical Art templates, which are licensed under a Creative Commons Attribution 3.0 Unported License; <https://smart.servier.com>

which Rab-GTPases C9ORF72 can interact, four groups performed interactome experiments. In SH-SY5Y cells, C9ORF72 colocalizes and co-immunoprecipitates (IPs) with Rab1, Rab5, Rab7, and Rab11 [47]. Another study, using C9ORF72 overexpression in COS-7 cells, did not find interactions with the above-listed Rab-GTPases but with a large number of other Rabs (Rab5A, 8A, 10, 13, 15, 18, 19, 27A, 28B, Rab7L1, 38, 40A, and 42) [5]. However, another very recent study in HEK293 cells reported interactions between C9ORF72 and Rab3A, 3B, 3C, and 3D, but not with Rab1A, Rab7A and Rab5A [53]. Finally, a fourth study did not detect any of these interactors nor other proteins involved in autophagy or endocytosis in neuronal cells (N2A cells) overexpressing C9ORF72. Instead, this study reports

an enrichment for proteins with mitochondrial functions [15]. One explanation for these discrepancies is that interactome composition is strongly influenced by bait expression levels, experimental set-up, or cell type. Nevertheless, these observations support a strong link between C9ORF72 and Rab-GTPases.

In iMNs, C9ORF72 strongly colocalizes with Rab5-positive endosomes (Fig. 1) and rarely with Lamp1-positive late endosomes/lysosomes [194]. Density gradients reveal that C9ORF72 co-segregates with light fractions (positive for EEA1) but not with heavy fractions (positive for Lamp1) [194], suggesting that C9ORF72 acts primarily on early endosomes. Interestingly, in C9ORF72 ALS/FTD iMNs from patients and spinal motor neurons in

Nestin-Cre;C9orf72^{fl/fl} mice, the number of Lamp1-, 2-, and 3-positive vesicles is decreased, as compared to control [194]. This implicates C9ORF72 in the control of protein degradation. For protein degradation through the endosomal pathway (for autophagy, see Sect. 3), early endosomes need to mature. The transformation from early to late endosomes requires a so-called Rab5/Rab7 conversion. Conversion from Rab5 to Rab7 on early endosomes involves interactions between activated Rab-GTPases and Vsp26, Vsp29, and Vsp35 [105]. Therefore, disturbed Rab function and decreased Vsp26 levels [5] due to *C9ORF72* haploinsufficiency may converge during this step of endosomal maturation. In all, these observations support a model in which reduced C9ORF72 expression maintains early endosomes in an inactive state, preventing maturation and eventually protein degradation. Reduced degradation may have several consequences. As outlined above, it could contribute to hyperexcitability and glutamate toxicity. Furthermore, changes in TrkB signalling may promote MN degeneration, as these receptors normally regulate cell survival [193]. TrkB has been shown to signal from Rab5- and Rab7-positive endosomes [67]. Decreased endocytosis of TrkB receptors in neurons with decreased C9ORF72 expression could affect signalling cascades regulating neuronal survival (Fig. 1). Finally, reduced protein degradation may contribute to the accumulation of proteins or DPRs in aggregates, a hallmark of ALS pathology [15] (Fig. 1).

Disrupted receptor trafficking in ALS has also been linked to TDP-43 (TAR-DNA-binding protein of 43 kDa). TDP-43 binds RNA and modulates multiple RNA processes including RNA synthesis, splicing, stability, and transport [103]. It is likely to function in multi-protein/RNA complexes [51, 102, 153], is involved in regulation and biogenesis of miRNAs [21, 82], and binds DNA which leads to repression of gene transcription [1]. In normal brain, TDP-43 localizes to the cell nucleus [124]. However, SALS cases and most FALS cases (together over 95% of ALS patients) display cytoplasmic TDP-43 inclusions accompanied by nuclear depletion of the protein in affected cells [107, 161]. In addition, some FALS patients have *TDP-43*-specific gene mutations that affect TDP-43 localization and function [151]. Most of the work linking TDP-43 to intracellular receptor trafficking derives from experiments that use knockdown or overexpression of TDP-43. TDP-43 knockdown leads to reduced ErbB4 and EGFR1 cell surface expression because of delayed surface recovery following receptor activation [150], which suggests defects in receptor recycling. EGF-EGFR signalling promotes survival, maturation, and outgrowth of neurons [25, 90] and, therefore, decreased EGFR1 cell surface expression, as a consequence of TDP-43 knockdown, is likely to affect neuronal survival or axonal innervation.

TDP-43 depletion in *Drosophila* affects BMP receptors. BMP signalling occurs on the early endosomes from where BMP receptors enter either the recycling pathway to the cell surface or are targeted for endo-lysosomal degradation [36]. Deshpande et al. show that synaptic growth is facilitated through the phosphorylation of MAD downstream of BMP receptors. MAD phosphorylation is significantly decreased in *Drosophila* motor neurons following overexpression or depletion of TDP-43 [35]. On basis of these observations, the authors suggest that reduced signalling of BMP receptors caused by non-equilibrated TDP-43 levels induces receptor missorting towards the early/recycling endosomes ultimately affecting neuronal and synaptic growth [35].

Alsin-2 is another gene that has been linked to defective endosomal trafficking in ALS. Alsin-2 (ALS2) is a 185 kDa protein which contains an ATS1/RCC1-like domain, a RhoGEF domain, and a vacuolar protein sorting 9 (VPS9) domain. Alsin-2 functions as a guanine-nucleotide exchange factor (GEF) for Rab5 and localizes with Rab5 on the early endosomal compartments. At least 12 different mutations in ALS2 have been reported in juvenile ALS and primary lateral sclerosis (PLS). These mutations have been described as frameshift, missense, or nonsense mutations [26]. Of these, two mutations found in the RCC-1 domain result in frame shift mutations that cause juvenile ALS (ALS2) [92, 132, 192]. Co-expression of Rab5 and a truncated form of Alsin-2 (containing MORN motifs and the VPS9 domain) prevents endosomal fusion. To establish the role of ALS2, effects on endosomal trafficking were studied in an *Alsin-2^{-/-}* mouse model. Hippocampal neurons of *Alsin-2^{-/-}* mice show accumulation of Rab5-positive endosomes, decreased Rab5 mobility, and increased colocalization of Rab5 with Lamp1. In addition, *Alsin-2^{-/-}* hippocampal neurons show faster degradation of AMPA receptors following stimulation [94]. These experiments suggest that Rab5 endosomes remain in their GDP-bound state and, consequently, interact to a lesser extent with downstream effectors. Inactive downstream effectors, such as the sorting machinery or motor proteins, could lead to decreased transport, decreased sorting (either into the recycling or the degradative pathway), and affect receptor activation due to decreased recycling.

Some ALS mutations are thought to affect endosomes at the level of lysosomal degradation. ALS-associated mutations in charged multivesicular body protein 2B (*CHMP2B*) and spastic paraplegia-11 (*SPG11*) have been reported to deregulate endosomal trafficking towards degradation. Loss-of-function of SPG11 affects endo-lysosomal homeostasis, anterograde trafficking, and lysosomal turnover [34]. CHMP2B is a subunit of the endosomal-sorting complex required for transport-III (ESCRT-III) which is required for the formation and fission of intra-luminal vesicles in the late endosomes/multivesicular bodies. Proteins within

intra-luminal vesicles are then delivered to lysosomes for degradation via endo-lysosomal fusion. Mutations in *CHMP2B* lead to lysosomal storage pathology and a decrease in neuronal endo-lysosomal motility. Interestingly, this trafficking defect could be rescued by knockdown of the FTD risk factor TMEM106B [43]. Mutations of *CHMP2B* and *SPG11* could increase susceptibility to neuronal death by deregulation of protein degradation.

Exome sequencing revealed that mutations in valosin-containing protein (**VCP/p79** or **ALS14**) account for 1–2% of FALS [79]. VCP/p97 regulates endo-lysosomal sorting of ubiquitinated cargos such as caveolin-1 and loss of VCP/p97 accelerates the accumulation of autophagosomes. [133]. Therefore, VCP/p97 mutations may affect maturation and degradation of autophagosomes and endo-lysosomes through impaired fusion with lysosomes [79, 133].

Another protein that may link ALS and processes such as endosomal trafficking and protein degradation is Fig4. Fig4 is a member of the SAC phosphatase family which removes the 5-phosphate from PI(3,5)P₂ to form PI(3)P [24, 42, 48, 146, 178]. Phosphatidylinositol 3-phosphate (PI(3)P) and its subclasses mediate several cellular functions such as membrane identity, endosomal trafficking, signalling, autophagy, and degradation [109]. The generation of these distinctive pools of PI3-phosphates occurs via three classes of PI3-kinases and different PI(3)Ps can localize to distinct endosomal compartments and thereby define membrane identity [109]. Fig4 forms a complex with two other proteins: VAC14, a scaffolding protein, and FAB1, a kinase that generates PI(3,5)P₂ from PI(3)P [78]. Mutations in *FIG4* have been found in patients with ALS [29, 131] and at least 14 rare non-synonymous *FIG4* variants were detected in ALS cases in a group of 201 central European ALS patients [131]. ALS variants include two protein-truncation mutations, two mutations in consensus splice sites, and six missense mutations, all suspected to interfere with protein function [29]. However, the contribution of *FIG4* variants to ALS needs further genetic confirmation since no deleterious *FIG4* variants have been reported in larger cohorts. In addition, some non-penetrant *FIG4* variant carriers have been described [131]. Nevertheless, Fig4 is an interesting candidate and its altered expression or function may affect endosomal maturation in ALS. For example, the conversion from PI(3)P to PI(3,5)P₂ is crucial for endosomal maturation, since Rab5/Rab7 conversion and the synthesis of PI(3,5)P₂ from PI(3)P regulate transformation from early to late endosomes. PI(3,5)P₂ has been shown to modulate several important functions at late endosomes/lysosomes, and thereby cargo degradation [130, 183]. Future studies should focus on establishing whether ALS-associated *FIG4* variants affect PI(3,5)P₂ levels and thereby disrupt the degradative pathway, e.g., by impaired endosomal maturation.

In conclusion, several of the gene defects that have been identified in ALS patients suggest a role for defective endosomal and receptor trafficking in the pathogenesis of this neuromuscular disease. Evidence is strongest for patients carrying hexanucleotide repeat expansions in *C9ORF72*. *C9ORF72* is a Rab-GEF, binds a large number of different Rab-GTPases, and has a role in vesicle transport. *C9ORF72* ALS/FTD patient cells show defects in lysosomal degradation and cell surface accumulation of receptors such as glutamate receptors. This may lead to enhanced neuronal excitability and glutamate toxicity. Furthermore, *C9ORF72* loss of function is likely to cooperate with gain of function mechanisms, leading, for example, to accelerated DPR accumulation. Manipulation of the expression of TDP-43 and Alsin-2 also induces receptor and endosomal trafficking defects, while it will be interesting to assess whether *FIG4*, *VCP*, *CHMP2B*, or *SPG11* variants associated with ALS affect these pathways, as well. Overall, these observations suggest a central role for receptor and endosomal trafficking in the pathogenesis of ALS.

Autophagy dysregulation

A key pathological hallmark of ALS is the mislocalization of (disease-associated) proteins and the formation of protein aggregates [15]. Defective protein degradation contributes to these pathological events and abnormal autophagy has been linked to ALS. Autophagy is an important protein degradation pathway involved in the clearance of protein aggregates and damaged organelles. It is highly dependent on intracellular transport of vesicles (e.g., lysosomes and autophagosomes) by motor proteins and, therefore, discussed in this review. Three types of autophagy have been described: microautophagy, macroautophagy, and chaperone-mediated autophagy. Macroautophagy is the main pathway used to eradicate damaged organelles and proteins [61] and is discussed below in relation to a few key ALS-associated proteins. For a more extensive discussion on the role of autophagy in ALS, see [45, 139].

Autophagy is initiated by the assembly of an isolation membrane with a cup-like shape. This membrane, the so-called phagophore, is built at the phagophore-assembly site (PAS) which is a nucleated site reported to be on ER, ER–mitochondria, ER–plasma membrane, as well as the plasma membrane, Golgi complex, and recycling endosomes (for review, see [38, 61]). The molecular details of phagophore nucleation are incompletely understood, but involve recruitment of ATG proteins to the PAS. There, ATG proteins interact with other proteins, and according to these interactions, ATGs are grouped into five complexes (for review, see [38, 61]). One of these complexes, the class 3

PI3-Kinase complex, is targeted by superoxide dismutase 1 (SOD1). SOD1 is a homo-dimeric metalloprotein that dismutates free superoxide radicals that cause oxidative stress. Over 180 mutations have been found in *SOD1*. VPS34 converts PI into PI(3)P and interacts with Beclin1, p115, ATG14, and PI3-Kinase in one complex. Mutant SOD1 impedes the vesicle nucleation step of autophagy through abnormal interaction with Beclin-1 and, consequently, destabilization of the Beclin-1–Bcl-x_L complex [98].

Fused in sarcoma (FUS) is a DNA/RNA-binding protein with functional homology to TDP-43 [96]. It associates with the transcription machinery and influences transcription initiation and promoter selection [93]. Many *FUS* mutations in ALS affect its nuclear localization signal (NLS) and mutant *FUS* is thought to act through both gain- (protein aggregation) and loss-of-function (nuclear depletion) mechanisms [95, 107]. FUS is a major component of cytoplasmic stress granules and these FUS-containing stress granules colocalize with autophagosomes. When mutant FUS is overexpressed in primary neurons, autophagy is decreased, while, simultaneously, the number of FUS-positive stress granules is increased [147]. Another study shows that overexpression of *FUS*^{P525L} and *FUS*^{R522G} impairs autophagy in neuronal cell lines and primary cortical neurons. Here, mutant FUS expression results in the formation of fewer omegasomes, which are precursors to autophagosomes. In addition, these precursors recruit less ATG9 and lipidated LC3-II, required for autophagy initiation and elongation. Therefore, mutant FUS appears to inhibit autophagy by interfering with early autophagosome formation.

Several lines of evidence link **TDP-43** to autophagy. TDP-43 aggregates colocalize with autophagy markers such as LC3 and p62/SQSTM1 (Sequestosome 1 (SQSTM1, also known as ubiquitin-binding protein p62) [70]. Furthermore, VCP and optineurin (OPTN), which colocalize with TDP-43, p62/SQSTM1, and ubiquitin, colocalize in spinal motor neurons of sporadic ALS patients [11]. Furthermore, elevated levels of LC3 have been found in skin biopsies of patients carrying the TDP-43^{A315T} mutation, suggesting that ALS-associated TDP-43 mutations may enhance autophagy [180]. In all, these data link SOD1, FUS, and TDP-43 mutations to autophagy dysregulation, suggesting that part of the pathogenic effects of these mutations may derive from their ability to affect protein or organelle removal.

In **C9ORF72** ALS/FTD patients, p62, a protein targeting cargo for autophagy, accumulates in the cerebellum, hippocampus, and neocortex, suggesting impaired autophagy [3, 30, 108]. P62 interacts with C9ORF72 [152], and increased levels of p62 are detected in C9ORF72 patient-derived fibroblasts [5]. Furthermore, following C9ORF72 knockdown in neurons, autophagy is impaired and both p62 and TDP-43 accumulate in aggregates [152]. This accumulation may be explained by defective Rab signalling as several of the Rabs

that are involved in the formation of autophagosomes bind the Rab-GEF C9ORF72 (such as Rab1A, 8A, and 39B) [31, 182]. In addition, C9ORF72 forms a complex with SMCR8 and WDR41 [152], which act as GDP/GTP exchange factors for Rab8A and Rab39B. Another Rab-GTPase linked to C9ORF72-mediated autophagosome formation is Rab1A [5]. C9ORF72 interacts with Rab1A and the ULK1 complex to regulate initiation of autophagy [182]. Two studies, using HeLa and SH-SY5Y cells, report that depletion of C9ORF72 reduces the formation of LC3-positive autophagosomes [47, 182], which are double-membrane vesicles that deliver cargo to lysosomes for degradation, while overexpression increases autophagy [182]. Other work reports increased levels of p62 and LC3 in Western Blots from C9ORF72 patient fibroblasts. Similarly, analysis of mouse embryonic fibroblasts (MEFs) and neuronal precursors from *C9ORF72*^{-/-} stem cells shows an increase in LC3 [175]. This study suggests that higher levels of LC3 would indicate higher levels of autophagy. However, transmission electron microscopy of iMNs from C9ORF72 ALS patients reveals swollen and, therefore, likely non-functional, autophagosomes. This could indicate disrupted degradation of autophagosomes and decreased autophagy [5]. Another study reports increased autophagy flux caused by an increase in transcription factor EB (TFEB), a master regulator of lysosome biogenesis [154]. Consistent with increased autophagy flux, this study detects a decrease in p62 levels in brain tissue from *C9ORF72*^{-/-} mice and in *C9ORF72*^{-/-} MEFs [175]. The apparent discrepancies between these different studies may result from the use of different cell types (i.e., HeLa cells, SH-SY5Y cells, MEFs, neuronal precursors, and iMNs) or from the use of different experimental approaches to decrease or deplete C9ORF72 (ranging from siRNA-mediated knockdown to depletion of C9ORF72 in KO mice and patient-derived C9ORF72 iMNs with lower *C9ORF72* expression, RNA foci and DPRs). Nevertheless, these data link disrupted autophagy to C9ORF72 hexanucleotide repeat expansions and C9ORF72 loss of function. Reduced protein degradation may contribute to the accumulation of proteins or DPRs in aggregates, a hallmark of ALS pathology [15] (Fig. 1). Therefore, in C9ORF72 ALS/FTD, loss and gain of function phenotypes (e.g., glutamate toxicity and impaired clearance of toxic DPRs) may cooperate to induce MN degeneration, as has been suggested on basis of work in C9ORF72 patient-derived deficient iMNs [194]. Here, the authors suggest that C9ORF72 haploinsufficiency may trigger defects in lysosomal biogenesis that impair the clearance of DPRs, generated from C9ORF72 repeat expansions, thereby exacerbating the toxic effects of these polypeptides.

Mutations in ubiquilin-2 (**UBQLN2**) cause X-linked juvenile and adult-onset ALS and ALS/dementia [185]. ALS-associated mutations in UBQLN2 cause a failure in




Fig. 2 ALS-associated mutations disrupt axonal transport by affecting motor and cytoskeletal proteins. **a** ALS-associated mutations in the C-terminal part of kinesin-5A (KIF-5A), a member of the kinesin family, cause ALS. These mutations are thought to affect cargo binding. Other ALS-associated mutations, such as in *SOD1* or *FUS*, affect kinesins indirectly, e.g., by altering expression levels or phosphorylation state. Mutations in p150^{Glued}, a subunit of the dynein/dynactin complex, have been implicated in ALS and affect binding of p150^{Glued} to microtubules. Defective motor proteins have been firmly linked to ALS pathogenesis and may affect motor neuron physiology by dysregulating the transport of essential cargo such as mitochondria, autophagosomes, growth factors, and signalling cues.

b Accumulation of cytoskeletal proteins such as neurofilaments is a pathological hallmark of ALS. ALS-associated mutations in *SOD1*, *FUS*, *TDP43*, and *C9ORF72*, but also in cytoskeletal proteins, such as neurofilament heavy chain (NFH), peripherin (PRPH), and tubulin beta-4A (*TUB4A*), cause accumulation of cytoskeletal proteins, disruption of neurofilament network assembly, decreased re-polymerization, and reduced actin-binding abilities. Eventually, these defects will disrupt cargo transport and, consequently, affect synaptic transmission, energy supply, and signalling cascades. This figure was created using Servier Medical Art templates, which are licensed under a Creative Commons Attribution 3.0 Unported License; <https://smart.servier.com>

the delivery of cargo to the proteasome leading to defective protein degradation and cell toxicity [27].

Mitophagy is removal of damaged mitochondria through autophagy. This removal is regulated by the PINK1-PARKIN pathway which poly-ubiquitinates damaged mitochondria to promote mitophagy. This ubiquitination recruits Tank-binding kinase 1 (TBK1) which phosphorylates OPTN and p62, both of which serve as autophagy adaptors for ubiquitinated proteins targeting them to the phagophore [129, 134, 188]. Mutations in *OPTN* (aka FIP-2) are associated with normal tension glaucoma and ALS. OPTN binds ubiquitin and functions as an autophagy receptor [184]. The addition of poly-ubiquitin chains by PINK-PARKIN, as well as phosphorylation by TBK1, promotes the rapid recruitment of OPTN, nuclear dot protein 52 kDa (NDP52), SQSTM1/p62, and Tax1-binding protein 1 (TAX1BP1) to damaged mitochondria, and this recruitment is blocked by inhibition or deletion of TBK1. TBK1 loss of function has been

reported to cause FTD/ALS [60, 129], possibly by affecting autophagosome formation due to reduced phosphorylation and recruitment of OPTN and p62. Following phosphorylation and association with damaged mitochondria, OPTN recruits LC3 via its LC3-interacting region (LIR) domain, resulting in autophagosome formation around mitochondria [69, 97, 188]. At a later stage in autophagy, OPTN binds the myosin VI motor protein, facilitating autophagosome maturation and fusion to lysosomes (see below within the *C9ORF72/SMCR8/WDR41* pathway) [174].

In addition to its role in autophagy, TBK1 is an NF- κ B effector by phosphorylating the NF- κ B inhibitors α /NFKBIA, IKKBK, or RELA to translocate NF- κ B to the nucleus. NF- κ B activation can occur during signalosome assembly downstream of OPTN [200]. The NF- κ B protein complex is crucial for the regulation neuronal survival and acts downstream of TrkB activation [8, 23] linking TBK1 to survival signalling downstream TrkB receptors.

In conclusion, the identification of ALS-associated genetic defects in *SOD1*, *FUS*, *TDP-43*, *C9ORF72*, *TBK1*, and *OPTN*, and the abnormalities in protein homeostasis and autophagosomes associated with these defects support an important role for dysregulated autophagy in ALS pathogenesis. Most studies show reduced autophagy due to hexanucleotide expansions or *C9ORF72* loss of function, but other data hint at enhanced autophagy. Therefore, further work is needed to dissect the precise autophagy defects associated with *C9ORF72* pathology. Similarly, while mutant *SOD1*, *FUS*, and *TDP-43* affect autophagy and *TBK1* and *OPTN* play a role in autophagy, the precise pathological effects of ALS-associated mutations in these genes remain incompletely understood. However, it is clear that altered autophagy plays a key role in ALS pathogenesis and contributes to motor neuron degeneration by inducing a failure to remove toxic proteins and damaged organelles, and allowing accumulation of proteins in aggregates.

Altered transport to and from ER and Golgi in ALS

In Sects. 2 and 3, a role for *C9ORF72* in endosomal transport and autophagy was discussed. However, **C9ORF72** has also been linked to disrupted ER–Golgi transport in ALS. Once synthesized, proteins targeted for the secretory pathway enter the endoplasmic reticulum (ER). There, proteins are folded by ER-resident enzymes and chaperones [17]. Correctly folded proteins leave the ER at specialized sites called ER exit sites (ERES) via coat protein complex II (COPII)-coated vesicles and form tubular-like structures known as the ER–Golgi intermediate compartment (ERGIC) and subsequently fuse with the Golgi [6, 145]. COPII-coat-mediated transport between the ER and Golgi is facilitated by Rab1 and Rab2, while trafficking from ERGIC back to the ER is regulated by Rab2 in a COPI-dependent fashion or by Rab6 in a COP-independent manner [18, 68]. In the ERGIC, additional sorting takes place where proteins are either transported further towards the Golgi or are recycled back to the ER [64, 111]. Several lines of experimental evidence suggest that dysregulation of *C9ORF72* may impact these different transport routes. First, *C9ORF72* associates with Rab1 and may modulate COPII-dependent ER–Golgi transport [47]. Furthermore, *C9ORF72* knockdown impairs endocytic trafficking from the plasma membrane to Golgi [5]. This is in line with the interaction of *C9ORF72* with Rab11 endosomes, which mediate recycling from the plasma membrane through the trans-Golgi network (TGN) [47]. Finally, *C9ORF72* is GEF for Rab8 [152], which regulates vesicular traffic between the TGN and the basolateral plasma membrane [73]. Another ALS-associated protein known to interact with Rab8 is **OPTN** [173]. It has been hypothesized

that ALS mutations in *OPTN* affect trafficking of Rab8-positive endosomes [122]. Together, these data link ALS-associated proteins via Rab-GTPases to intracellular trafficking to and from ER/Golgi. The precise functional effect of ALS mutants on this trafficking and the underlying molecular mechanisms require further study.

Members of the vesicle-associated membrane protein-associated protein (VAP) family, such as VAPA and VAPB, are present in the ER and regulate ER and Golgi transport to maintain Golgi complex identity and ER morphology, as well as lipid transfer [99, 137, 160, 171]. In addition, VAPB interacts with ER–Golgi recycling proteins and modulates the delivery of membrane to dendrites [91]. A dominant missense mutation, P56S, in the MSP domain of VAPB causes FALS8 [127]. VAPB^{P56S} accumulates in inclusions containing disrupted ER [135, 171]. Furthermore, it recruits wild-type VAPA/B into such inclusions. It has, therefore, been proposed that VAPB^{P56S} has a dominant-negative effect on VAP function [171]. Interestingly, VAP protein levels are reduced in SALS patients, *SOD1* mutant mice, and ALS patient-derived MNs [4, 113, 171]. YIF1A, a transmembrane protein that plays an important role in secretion [12, 195], binds to VAPB and the ALS-mutant VAPB^{P56S} [91]. YIF1A cycles between the ER and Golgi and is mainly localized to the ERGIC. However, following expression of the ALS-mutant VAPB^{P56S}, YIF1A fails to localize to the ERGIC causing the disruption of this structure. This event has been suggested to contribute to motor neuron degeneration [91].

Mutations in **SOD1** affect trafficking at the Golgi in several ways. For example, the ALS-associated mutations *SOD1*^{A4V}, *SOD1*^{G85R}, and *SOD1*^{G93A} disrupt the secretory pathway. In one study, BDNF was used as a marker of ER–Golgi protein secretion in the presence of *SOD1* mutant protein and BDNF levels were significantly higher in conditioned medium of untransfected cells, cells expressing *SOD1*^{WT} or EGFP controls as compared to medium from *SOD1*^{A4V}, *SOD1*^{G85R}, and *SOD1*^{G93A} transfected cells. In contrast, intracellular levels of BDNF in *SOD1*^{A4V}, *SOD1*^{G85R}, and *SOD1*^{G93A} transfected cells were higher as compared to controls, hinting at defects in secretion [9]. In addition to defects in secretion, the *SOD1*^{A4V} mutation triggers ER stress causing inclusions and apoptosis, while overexpression of COPII rescues the above-mentioned *SOD1*-mutant phenotypes. This suggests that misfolded *SOD1* interferes with ER-to-Golgi trafficking via COPII vesicles. Overall, these defects in the secretory pathway and the resulting accumulation of secretory proteins could explain how *SOD1*-induced ER stress leads to apoptosis [9].

In addition to the secretory pathway, *SOD1* mutations inhibit transport from ERGIC to Golgi, but not from ER to ERGIC [159]. ER-to-ERGIC transport is affected by mutant **TDP-43** and mutant **FUS**. Both affect Rab1-dependent trafficking of COPII vesicles, which disrupts transport from ER

to ERGIC. Interestingly, overexpression of Rab1 rescues this defect [104, 159]. TDP-43 is localized at the cytoplasmic face of the ER membrane, while FUS localizes within the ER, inhibiting transport at two different sites [159]. Even though the exact mechanism through which Rab1 trafficking is affected remains elusive, disrupted vesicle trafficking from Golgi has been reported to cause Golgi fragmentation, a hallmark of many neurodegenerative diseases, including ALS [55, 56, 62]. It has been shown that depletion of Golgi-associated Rabs causes destabilization of the Golgi [57]. Interestingly, Golgi-associated vesicular trafficking is inhibited in cells expressing different ALS-mutant proteins (SOD1, FUS, TDP-43, and OPTN [10, 39, 159, 165]). Defective ER–Golgi transport precedes all other cellular pathologies in addition to fragmentation, including ER stress, protein aggregation, inclusion formation, and apoptosis [9]. Overall, these data suggest that altered ER–Golgi transport may be one of the first disease mechanisms through which ALS-mutant proteins affect motor neuron function and survival.

Apart from protein folding and quality control, the ER forms structural connections with mitochondria, which facilitate a number of cellular functions such as energy metabolism, Ca^{2+} homeostasis and lipid metabolism. Interestingly, mitochondria–ER contact sites occur on acetylated microtubules [54] (see Sect. 5). The disruption of ER–mitochondria associations has been linked to Alzheimer’s disease [7] and ALS. **VAPB** proteins localize to the ER and interact with mitochondrial protein tyrosine phosphatase-interacting protein-51 (PTPIP51) to regulate ER–mitochondria interactions. TDP-43, both wild-type and ALS mutants TDP-43^{M337V}, TDP-43^{Q331K}, TDP-43^{A382T}, or TDP-43^{G348C}, perturb ER–mitochondria interactions by disrupting VAPB–PTPIP51 binding [164]. In addition to TDP-43, FUS also affects ER–mitochondria interacting sites. FUS activates GSK3- β which disrupts VAPB–PTPIP51 and ER–mitochondria interactions [163]. It is, therefore, tempting to speculate that mutations in VAPB, TDP-43, and FUS may contribute to ALS pathogenesis by interfering with energy metabolism at the level of ER–mitochondria interactions.

In conclusion, trafficking pathways from and to the ER and Golgi complexes, and between ER and Golgi, are a major target in ALS. In part, these defects involve Rab-GTPases and their effectors. The precise molecular details of how these defects result in motor neuron degeneration remain largely unknown. However, defective trafficking from Golgi can lead to Golgi fragmentation, a major hallmark of ALS and other neurodegenerative diseases. Interestingly, some of the reported defects (ER-to-ERGIC) can be rescued by Rab1 overexpression, highlighting Rab-GTPases as potential therapeutic targets. Moreover, perturbations in ER–mitochondria contacts as a consequence of VAPB,

TDP-43, or FUS mutations could affect energy metabolism, Ca^{2+} homeostasis, and lipid metabolism.

Disrupted axonal transport in ALS

Axonal transport of cargo such as mitochondria, signalling endosomes, or proteins between the cell body and distant cellular sites, e.g., synapses, is essential for neuronal function and survival (Fig. 2). Defects in axonal transport are linked to ALS and mutations in different proteins that form the axonal transport machinery have been reported in ALS patients. Changes in axonal transport are one of the first pathological hallmarks of ALS and may be an early and key pathogenic event. Two main classes of axonal transport are distinguished, i.e., slow and fast axonal transport, both of which appear to be affected in ALS. These types of transport differ with respect to the speed by which cargo is moved, but both are mediated by the same molecular machinery. Axonal cargo is moved in antero- and retrograde directions by motor proteins, such as kinesins and dynein, along microtubule polymers. Other proteins linked to axonal transport have been implicated in ALS, but, here, we focus on affected motor proteins and the cytoskeleton for which genetic and pathological evidence is strongest. For a more extensive overview and discussion on axonal transport defects, specific cargos, and other transport proteins in ALS, we refer to the other recent reviews [83, 179].

The human kinesin superfamily of molecular motor proteins contains 45 members which mediate both slow and fast anterograde axonal transport. Strongest evidence for the involvement of kinesins in ALS pathogenesis is provided by three studies that reveal mutations in kinesin-5A (**KIF5A**) that cause ALS [20, 198, 126] (Fig. 1). This work identifies mutations in the KIF5A C-terminus which binds cargo-adaptor proteins [123, 140]. These mutations are, therefore, predicted to cause disruption of cargo-binding inducing loss-of-function phenotypes [20]. This hypothesis is in line with the observation that *Kif5a*^{-/-} mice show neurodegeneration and paralysis [191]. Intriguingly, mutations in the kinesin motor domain and coiled-coil domain within the N-terminal part of KIF5A have been reported in Hereditary spastic paraplegia (HSP) and Charcot–Marie–Tooth (CMT) patients [65, 80]. This indicates that KIF5A may be a central target in motor neuron disease.

Kinesins are likely to also be affected indirectly in ALS, for example by mutations in FUS and SOD1. Mutations in **FUS** dysregulate *KIF5C*, *KIF1B*, and *KIF3A* mRNA expression [72] and could thereby modulate cargo transport. ALS-associated SOD1 and FUS mutants also impair fast axonal transport [59, 117, 149]. Furthermore, disruption of anterograde transport by misfolded human **SOD1**^{H46R} protein in isolated squid axoplasm involves p38 MAP Kinase

(p38 MAPK) activation and kinesin-1 phosphorylation [16]. p38 MAPK phosphorylates kinesin-1, thereby inhibiting its translocation along microtubules [117]. Inhibition of p38 MAPK protects mutant *SOD1*-expressing motor neurons [37]. How p38 MAPK inhibition acts neuroprotective is unknown but may involve effects on kinesin activity.

Retrograde axonal transport is facilitated by the motor protein dynein 1 [71]. Dynein 1 is composed of two homodimerized dynein heavy chain and multiple dynein intermediate and light chains [87]. The function of this complex is regulated by adapter complexes including dynactin. The dynactin complex contains p150^{Glued} together with other proteins. Mutations in *DCTN1*, which encodes p150^{Glued}, are reported in both SALS and FALS patients [120] (Fig. 1). These ALS-causing mutations impede binding of p150^{Glued} to microtubules, resulting in dysfunctional dynein/dynactin-mediated transport of cargos such as autophagosomes [75, 101]. As described earlier for kinesins, mutations in p150^{Glued} or other components of the dynein/dynactin complex have been linked to various neurological disorders, several of which show motor neuron deficits [83, 179]. Motor neurons from *SOD1*^{G93A} transgenic mice display defective dynein-mediated retrograde transport, both in vitro and in vivo, linking *SOD1* mutations to dynein-mediated transport [14, 84]. Thus, defects in motor proteins are firmly linked to ALS pathogenesis and are predicted to affect motor neuron physiology through disruption of the transport of cargos such as mitochondria, growth factors, and RNA, thereby affecting energy metabolism, survival, and local translation.

Proper axonal transport not only relies on motor proteins but also on cytoskeletal components such as neurofilaments and microtubules. The accumulation of neurofilaments is a pathological hallmark of both FALS and SALS [121, 186] (Fig. 1). The deletion of neurofilament in *SOD1* transgenic mice delays disease onset and reduces progression of ALS pathology. This indicates that neurofilaments contribute to motor neuron toxicity [186]. Accumulation of neurofilaments or disruption of neurofilament growth could lead to stalling of cargo transport in neurons. Interestingly, the accumulation of neurofilaments in ALS may be caused by defects in kinesins and dynein, since neurofilament oligomers are transported by these motor proteins [138, 166].

Several different mutations in cytoskeletal proteins have been reported in ALS. These have been proposed to induce motor neurodegeneration by disturbing the cytoskeleton and disrupting cargo transport. For example, motor neurons of ALS patients with mutations in *neurofilament heavy chain* (*NFH*) display accumulations of phosphorylated neurofilament proteins that could disrupt axonal transport [115, 121]. Mutations in *peripherin* (*PRPH*) may act through a similar pathogenic mechanism. Peripherin is a neuronal intermediate filament protein and an ALS-causing frameshift mutation in *PRPH* disrupts neurofilament network assembly [63].

Furthermore, peripherin localizes to Bunina bodies, which are small eosinophilic intra-neuronal inclusions in the remaining lower motor neurons [114], which could affect cargo transport. Furthermore, ALS-causing mutations in *tubulin β -4A* (*TUB4A*) destabilize the microtubule network and reduce re-polymerization [158], therefore possibly affecting transport of cargo and microtubule assembly. Mutant SOD1 also affects microtubule dynamics, in part by interacting with tubulin or microtubule-associated proteins (for review [83, 179]).

Studies showing dysregulation or the therapeutic potential of HDAC6 (a class IIb histone deacetylase involved in microtubule stability [32]) in ALS further highlight the role of microtubules in ALS. ALS-associated mutations in *FUS* and *TDP-43* regulate HDAC6 expression [49, 86, 112]. Acetylation of α -tubulin is important for the binding of molecular motor proteins to microtubules [141, 148] and deletion of *HDAC6* significantly slows disease progression and prolongs survival in mutant *SOD1*^{G93A} mice [167]. These data identify HDAC6 inhibition as a potential therapeutic strategy in ALS. This is supported by the observation that HDAC6 inhibition reverses axonal transport defects in iPSC-generated motor neurons derived FUS-ALS patients [66].

In addition to the microtubule cytoskeleton, proteins such as profilin and cofilin have been implicated in ALS and indicate a role for the actin cytoskeleton. Profilin (*PFN1*) promotes nucleotide exchange on actin converting monomeric ADP-actin to ATP-actin [116]. PFN1-ATP-actin complexes bind to the fast-growing end of actin filaments regulating filament growth [172]. Patients with mutations in *PFN1* display atrophy of the limbs and it has been suggested that *PFN1* contributes to ALS pathogenesis by altering actin dynamics resulting in axon outgrowth inhibition [189]. This is consistent with the finding that the ALS-associated PFN1 mutants *C71G* and *M114T* display reduced actin binding and inhibit axon outgrowth of embryonic motor neurons [189]. In addition, *PFN1* mutants cause the formation of ubiquitinated, insoluble aggregates that colocalize with TDP-43 [189]. C9ORF72 interacts with cofilin (*CFL1*), a key regulator of actin dynamics [19]. Knockdown of *C9ORF72* expression reduces axonal growth and actin dynamics [157]. Reduced C9ORF72 levels observed in ALS could affect actin dynamics and thereby, for example, cargo trafficking along the actin cytoskeleton at axonal branches or synapses [13].

In summary, retrograde and anterograde axonal transport is crucial for the distribution of cargo in motor neurons. ALS-associated defects in motor proteins and the cytoskeleton, that both are required for cargo transport, are predicted to cause various molecular and cellular perturbations, e.g., in receptor signalling, synaptic function, gene regulation, energy metabolism, or lysosomal degradation that could lead

to motor neuron degeneration. However, our understanding of how defective motor and cytoskeletal proteins cause ALS and specifically affect MNs is rather incomplete. Further studies are needed to fill this void. Genetic and experimental evidence for a role for disrupted axonal transport in ALS pathogenesis is strong and has provided several starting points for the development of therapeutic strategies (for an overview see [83, 179]). For example, inhibition of p38 MAPK protects motor neurons from degeneration and HDAC6 depletion has positive effects on ALS disease progression and survival. However, further work is needed to implement these and other strategies. For examples, HDAC6 not only regulates axonal transport but is also known to play a crucial role in the clearance of protein aggregates by autophagy [81]. Therefore, strategies need to be developed that specifically affect the transport-mediated effects HDAC6.

Nucleocytoplasmic transport

A major pathological hallmark of ALS is the nuclear depletion and cytoplasmic accumulation of **TDP-43**, which is observed in over 95% of ALS patients [107, 161]. Consistent with this pattern of protein re-distribution, impaired nucleocytoplasmic transport has emerged as a disease mechanism in ALS and other neurodegenerative diseases (for review, see [46, 85]). Several lines of experimental evidence have recently implicated defects in nucleocytoplasmic transport in ALS. These include the presence of mutations in the nuclear localization signals (NLS) of proteins such as **FUS** and **hnRNPA1** [40, 96, 106]. **FUS** causes toxicity in part through the formation of abnormal aggregates in the nucleus and cytoplasm of affected neurons and glial cells in ALS patients with **FUS** mutations [95, 107]. Most of the reported **FUS** mutations in ALS are missense mutations affecting its C-terminal NLS [96]. Interestingly, the ALS-associated protein aggregates that form as a result of impaired nucleocytoplasmic trafficking may themselves also interfere with nucleocytoplasmic transport of protein and RNA [187]. Finally, repeat expanded **C9ORF72** has been proposed to affect trafficking between the nucleus and cytoplasm in different ways. As discussed before, disease-associated repeat expansions in **C9ORF72** induce motor neuron degeneration and ALS in part through toxic gain of function mechanisms. These include the accumulation of mutant transcripts and DPRs. Expanded repeat-containing **C9ORF72** transcripts accumulate in affected motor neurons, and other cells in the brain and spinal cord. Several studies suggest that these stable hexanucleotide repeat-containing **C9ORF72** RNA species sequester RNA-binding proteins and nuclear pore complex (NPC) components (e.g., **RanGAP1**).

This disturbs the function and nucleocytoplasmic trafficking of these and other proteins [197]. Mislocalization and accumulation of NPC proteins have also been observed in ALS cases linked to other mutations, such as **SOD1** [88, 155]. Another mechanism by which **C9ORF72** repeat expansion affects nucleocytoplasmic transport is the generation of DPRs. DPRs have been proposed to block the central channel of the nuclear pore [156]. However, how exactly RNA accumulation or DPRs disrupts nucleocytoplasmic transport remains incompletely understood (for review, see [52, 85]).

Central to nucleocytoplasmic transport is the NPC, a large protein complex that spans the membranes of the nuclear envelope and that is composed of about 30 different nucleoporins. A direct link between the NPC and **C9ORF72** is provided by work identifying components of the NPC (nucleoporins and nuclear transport receptors) as genetic modifiers of **C9ORF72**-related neurodegeneration and the binding of these components to DPRs (for review, see [85]). Reduced expression or mislocalization of components of the NPC and nuclear import factors, i.e., importins, in ALS brain and spinal cord tissue [88, 125, 128, 169] or caused by **TDP-43** aggregation in vitro [28] further implicates transport through the NPC in ALS pathology. Interestingly, mutations in the endosomal-sorting complexes required for transport (ESCRT) III subunit **CHMP2B** are causative for ALS [43]. Genetic ablation of ESCRT-III in yeast leads to clustering of defective NPCs due to mis-assembly [181]. It will, therefore, be interesting to assess whether **CHMP2B** mutations lead to defects in NPC assembly surveillance and thereby motor neuron degeneration.

In conclusion, defects in nucleocytoplasmic transport are increasingly recognized as a key event in the pathogenesis of ALS. Evidence for changes in nucleocytoplasmic trafficking are particularly strong in **C9ORF72** ALS/FTD. These include mislocalization of proteins forming or associating with the NPC and clogging of the NPC by DPRs. Despite this recent progress, our understanding of how defective nucleocytoplasmic transport leads to motor neuron degeneration and ALS remains rather incomplete. Furthermore, the relative importance of this proposed disease mechanism in comparison to the other ALS disease mechanisms remains to be established. Fundamental insight into the process of nucleocytoplasmic transport will help to dissect the role of defects in this process in ALS. This is exemplified by recent work, suggesting that the nuclear export signals (NES) of **TDP-43** and **FUS** are not functional and that these proteins may leave the nucleus by passive diffusion. Retention to synthesized RNAs sequesters them inside the nucleus and limits cytoplasmic diffusion [41]. This would suggest that defects in active nuclear export of **TDP-43** and **FUS** only play a minor role in ALS and helps to understand how these proteins accumulate in the cytoplasm in ALS.

Conclusions

Intracellular trafficking defects observed in ALS range from accumulation or mislocalization of cell surface receptors or disturbed ER/Golgi trafficking to perturbations in motor proteins and the cytoskeleton. This review highlights that these defects result from changes in molecular and cellular processes that are often not isolated events but rather steps of a continued trafficking pathway. A particular phenotype, such as protein accumulation, may be explained by changes in several of the steps of the trafficking process. For example, cell surface receptor accumulation could result from altered Rab function, defects in motor proteins carrying this cargo, or from changes in the cytoskeleton. In addition, these defects may also indirectly affect other processes. For example, downregulation of Rabs can result in altered expression of their effectors. This may induce up- or downregulation of Rab proteins in complementary networks [176] and cause defects such as uncontrolled budding or fusion of vesicles [74, 110].

While evidence is accumulating that trafficking defects significantly contribute to motor neuron death and ALS, our understanding how trafficking is affected and how these changes lead to ALS and could eventually be counteracted to treat this disease is rather incomplete. This situation is exemplified by a large number of recent studies on C9ORF72 ALS/FTD. C9ORF72 repeat expansions are known to lead to reduced C9ORF72 expression which is thought to affect protein degradation. At the same time, decreased C9ORF72 expression may trigger hyperexcitability through effects on glutamate receptors and thereby induce neuronal death. While the precise contribution of C9ORF72, loss of function to motor neuron degeneration remains unclear, the pathogenic gain of function effects of C9ORF72 repeat expansions, such as the formation of RNA foci and DPRs, also targets intracellular trafficking, e.g., axonal transport and nucleocytoplasmic trafficking. Finally, C9ORF72 loss and gain of function mechanisms may interact. It has been suggested that while *C9ORF72*^{-/-} mice do not show overt neurodegeneration [89], reduced C9ORF72 activity could impair the clearance of DPRs and thereby enhance the effects of these toxic proteins [194]. Future work is needed that systematically dissects the downstream effects of C9ORF72 repeat expansions and other ALS mutations on different aspects of intracellular transport. High-resolution live imaging, humanized culture models, and manipulation strategies such as CRISPR/CAS to perform gene knockout or induce epitope tags to endogenously label proteins of interest should be part of the toolbox to further explore the contribution of trafficking defects in ALS.

Many open questions with respect to intracellular trafficking and ALS remain. For example, how do intracellular

transport and protein aggregates interact and which are the functional consequences of this interaction. Protein aggregation is a pathological hallmark of ALS. TDP-43 aggregates are found in the majority of patients, while several other ALS-associated proteins are prone to aggregate, e.g., SOD1, FUS, and DPRs. Defects in intracellular trafficking are linked in several ways to disturbed protein homeostasis. First, in some cases, mutant proteins accumulate and start to form aggregates because of defects in transport, e.g., nucleocytoplasmic transport. Second, disrupted protein degradation due to perturbed intracellular trafficking may facilitate aggregate formation and stability. Third, aggregates can inhibit intracellular transport, e.g., axonal transport or nucleocytoplasmic trafficking. Thus, it is clear that intracellular trafficking contributes to aggregate formation, while aggregates disturb intracellular transport, but the precise molecular and functional details of these interactions remain to be dissected. While this review has focused on neuronal trafficking, non-neuronal cells such as glia cells may also contribute to ALS pathogenesis and trafficking defects. For example, activated microglia-conditioned medium induces neurite beading in cultured MNs via NMDA-R signalling. This signalling inhibits mitochondrial complex IV and a subsequent decline in ATP reduces fast axonal transport and accumulation of tubulin, neurofilament, kinesins, and dynein prior to MN death [168]. Therefore, further studies are needed to examine whether the intracellular trafficking defects observed in MNs are also at play in relevant populations of non-neuronal cells.

Finally, it is clear that at least some aspects of intracellular trafficking play a key role in ALS pathogenesis. Studies have begun to use these observations as starting points for designing novel therapeutic strategies for ALS (e.g., inhibition of p38 MAPK or HDAC6). Further insight into the role of defective intracellular transport will, therefore, undoubtedly provide further targets for the design of therapeutic interventions for ALS in the future.

Acknowledgements We thank Ronja Markworth for critically reading this manuscript. Work in the laboratories of the authors on motor neuron disease is supported by the Center for Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB) to KB and the Prinses Beatrix Spierfonds and the Dutch ALS Foundation to RJP.

Author contributions KB and RJP co-wrote this manuscript.

Compliance with ethical standards

Conflict of interest The authors declare no conflict of interests.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate

credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

- Abhyankar MM, Urekar C, Reddi PP (2007) A novel CpG-free vertebrate insulator silences the testis-specific SP-10 gene in somatic tissues: role for TDP-43 in insulator function. *J Biol Chem* 282:36143–36154. <https://doi.org/10.1074/jbc.M705811200>
- Al-Chalabi A, Hardiman O (2013) The epidemiology of ALS: a conspiracy of genes, environment and time. *Nat Rev Neurol* 9:617–628
- Al-Sarraj S, King A, Troakes C, Smith BMS, Bodi I, Rogelj B et al (2011) P62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTL and MND/ALS. *Acta Neuropathol* 122:691–702
- Anagnostou G, Akbar MT, Paul P, Angelinetta C, Steiner TJ, de Belleruche J (2010) Vesicle associated membrane protein B (VAPB) is decreased in ALS spinal cord. *Neurobiol Aging* 31:969–985. <https://doi.org/10.1016/j.neurobiolaging.2008.07.005>
- Aoki Y, Manzano R, Lee Y, Dafinca R, Aoki M, Douglas AGL et al (2017) C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia. *Brain* 140:887–897. <https://doi.org/10.1093/brain/awx024>
- Appenzeller-Herzog C (2006) The ER-Golgi intermediate compartment (ERGIC): in search of its identity and function. *J Cell Sci* 119:2173–2183. <https://doi.org/10.1242/jcs.03019>
- Area-Gomez E, Del Carmen Lara Castillo M, Tambini MD, Guardia-Laguarta C, De Groof AJC, Madra M et al (2012) Upregulated function of mitochondria-associated ER membranes in Alzheimer disease. *EMBO J* 31:4106–4123. <https://doi.org/10.1038/emboj.2012.202>
- Arumugam S, Mincheva-Tasheva S, Periyakaruppi A, de la Fuente S, Soler RM, Garcera A (2018) Regulation of survival motor neuron protein by the nuclear factor-kappa B pathway in mouse spinal cord motoneurons. *Mol Neurobiol* 55:5019–5030. <https://doi.org/10.1007/s12035-017-0710-4>
- Atkin JD, Farg MA, Soo KY, Walker AK, Halloran M, Turner BJ et al (2014) Mutant SOD1 inhibits ER-Golgi transport in amyotrophic lateral sclerosis. *J Neurochem* 129:190–204. <https://doi.org/10.1111/jnc.12493>
- Atkin JD, Farg MA, Walker AK, McLean C, Tomas D, Horne MK (2008) Endoplasmic reticulum stress and induction of the unfolded protein response in human sporadic amyotrophic lateral sclerosis. *Neurobiol Dis* 30:400–407. <https://doi.org/10.1016/j.nbd.2008.02.009>
- Ayaki T, Ito H, Fukushima H, Inoue T, Kondo T, Ikemoto A et al (2014) Immunoreactivity of valosin-containing protein in sporadic amyotrophic lateral sclerosis and in a case of its novel mutant. *Acta Neuropathol Commun*. <https://doi.org/10.1186/s40478-014-0172-0>
- Barrowman J, Wang W, Zhang Y, Ferro-Novick S (2003) The Yip1p-Yif1p complex is required for the fusion competence of endoplasmic reticulum-derived vesicles. *J Biol Chem* 278:19878–19884. <https://doi.org/10.1074/jbc.M302406200>
- Bharat V, Siebrecht M, Burk K, Ahmed S, Reissner C, Kohansal-Nodehi M et al (2017) Capture of dense core vesicles at synapses by JNK-dependent phosphorylation of synaptotagmin-4. *Cell Rep* 21:2118–2133. <https://doi.org/10.1016/j.celrep.2017.10.084>
- Bilsland LG, Sahai E, Kelly G, Golding M, Greensmith L, Schiavo G (2010) Deficits in axonal transport precede ALS symptoms in vivo. *Proc Natl Acad Sci*. <https://doi.org/10.1073/pnas.1006869107>
- Blokhuis AM, Koppers M, Groen EJM, van den Heuvel DMA, Dini Modigliani S, Anink JJ et al (2016) Comparative interactomics analysis of different ALS-associated proteins identifies converging molecular pathways. *Acta Neuropathol* 132:175–196. <https://doi.org/10.1007/s00401-016-1575-8>
- Bosco DA, Morfini G, Karabacak NM, Song Y, Gros-Louis F, Pasinelli P et al (2010) Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. *Nat Neurosci*. <https://doi.org/10.1038/nn.2660>
- Braakman I, Hebert DN (2013) Protein folding in the endoplasmic reticulum. *Cold Spring Harb Perspect Biol* 5:a013201. <https://doi.org/10.1101/cshperspect.a013201>
- Brandizzi F, Barlowe C (2013) Organization of the ER-Golgi interface for membrane traffic control. *Nat Rev Mol Cell Biol* 14:382–392
- Bravo-Cordero JJ, Magalhaes MAO, Eddy RJ, Hodgson L, Condeelis J (2013) Functions of cofilin in cell locomotion and invasion. *Nat Rev Mol Cell Biol* 14:405–417
- Brenner D, Yilmaz R, Müller K, Grehl T, Petri S, Meyer T et al (2018) Hot-spot KIF5A mutations cause familial ALS. *Brain* 141:688–697. <https://doi.org/10.1093/brain/awx370>
- Buratti E, De Conti L, Stuardi C, Romano M, Baralle M, Baralle F (2010) Nuclear factor TDP-43 can affect selected microRNA levels. *FEBS J* 277:2268–2281. <https://doi.org/10.1111/j.1742-4658.2010.07643.x>
- Burd C, Cullen PJ (2014) Retromer: a master conductor of endosome sorting. *Cold Spring Harb Perspect Biol* 6:a016774. <https://doi.org/10.1101/cshperspect.a016774>
- Burk K, Murdoch JD, Freytag S, Koening M, Bharat V, Markworth R et al (2017) EndophilinAs regulate endosomal sorting of BDNF-TrkB to mediate survival signaling in hippocampal neurons. *Sci Rep* 7:2149. <https://doi.org/10.1038/s41598-017-02202-4>
- Cantley LC (2002) The phosphoinositide 3-kinase pathway. *Science* 296:1655–1657
- Casper D, Mytilineou C, Blum M (1991) EGF enhances the survival of dopamine neurons in rat embryonic mesencephalon primary cell culture. *J Neurosci Res* 30:372–381. <https://doi.org/10.1002/jnr.490300213>
- Chandran J, Ding J, Cai H (2007) Alsin and the molecular pathways of amyotrophic lateral sclerosis. *Mol Neurobiol* 36:224–231
- Chang L, Monteiro MJ (2015) Defective proteasome delivery of polyubiquitinated proteins by ubiquilin-2 proteins containing ALS mutations. *PLoS One*. <https://doi.org/10.1371/journal.pone.0130162>
- Chou CC, Zhang Y, Umoh ME, Vaughan SW, Lorenzini I, Liu F et al (2018) TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. *Nat Neurosci*. <https://doi.org/10.1038/s41593-017-0047-3>
- Chow CY, Landers JE, Bergren SK, Sapp PC, Grant AE, Jones JM et al (2009) Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS. *Am J Hum Genet* 84:85–88. <https://doi.org/10.1016/j.ajhg.2008.12.010>
- Cooper-Knock J, Hewitt C, Highley JR, Brockington A, Milano A, Man S et al (2012) Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. *Brain* 135:751–764. <https://doi.org/10.1093/brain/awr365>
- Corbier C, Sellier C (2017) C9ORF72 is a GDP/GTP exchange factor for Rab8 and Rab39 and regulates autophagy. *Small GTPases* 8(3):181–186. <https://doi.org/10.1080/21541248.2016.1212688>

32. D'Ydewalle C, Krishnan J, Chiheb DM, Van Damme P, Irobi J, Kozikowski AP et al (2011) HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot–Marie–Tooth disease. *Nat Med* 17:968–974. <https://doi.org/10.1038/nm.2396>
33. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ et al (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. *Neuron* 72:245–256. <https://doi.org/10.1016/j.neuron.2011.09.011>
34. Denora PS, Smets K, Zolfanelli F, De Groote CC, Casali C, Deconinck T et al (2016) Motor neuron degeneration in spastic paraplegia 11 mimics amyotrophic lateral sclerosis lesions. *Brain*. <https://doi.org/10.1093/brain/aww061>
35. Deshpande M, Feiger Z, Shilton AK, Luo CC, Silverman E, Rodal AA (2016) Role of BMP receptor traffic in synaptic growth defects in an ALS model. *Mol Biol Cell* 27:2898–2910. <https://doi.org/10.1091/mbc.E16-07-0519>
36. Deshpande M, Rodal AA (2016) The crossroads of synaptic growth signaling, membrane traffic and neurological disease: insights from *Drosophila*. *Traffic* 17:87–101
37. Dewil M, dela Cruz VF, Van Den Bosch L, Robberecht W (2007) Inhibition of p38 mitogen activated protein kinase activation and mutant SOD1G93A-induced motor neuron death. *Neurobiol Dis*. <https://doi.org/10.1016/j.nbd.2006.12.023>
38. Dikic I, Elazar Z (2018) Mechanism and medical implications of mammalian autophagy. *Nat Rev Mol Cell Biol* 19:349–364
39. van Dis V, Kuijpers M, Haasdijk ED, Teuling E, Oakes SA, Hoogenraad CC et al (2014) Golgi fragmentation precedes neuromuscular denervation and is associated with endosome abnormalities in SOD1-ALS mouse motor neurons. *Acta Neuropathol Commun* 2:38. <https://doi.org/10.1186/2051-5960-2-38>
40. Dormann D, Rodde R, Edbauer D, Bentmann E, Fischer I, Hruscha A et al (2010) ALS-associated fused in sarcoma (FUS) mutations disrupt transportin-mediated nuclear import. *EMBO J*. <https://doi.org/10.1038/emboj.2010.143>
41. Ederle H, Funk C, Abou-Ajram C, Hutten S, Funk EBE, Kehlenbach RH et al (2018) Nuclear egress of TDP-43 and FUS occurs independently of Exportin-1/CRM1. *Sci Rep*. <https://doi.org/10.1038/s41598-018-25007-5>
42. Efe JA, Botelho RJ, Emr SD (2005) The Fab1 phosphatidylinositol kinase pathway in the regulation of vacuole morphology. *Curr Opin Cell Biol* 17:402–408
43. Clayton EL, Milioto C, Muralidharan B, Norona FE, Edgar JR, Soriano A et al (2018) Frontotemporal dementia causative CHMP2B impairs neuronal endolysosomal traffic-rescue by TMEM106B knockdown. *Brain* 141:3428–3442. <https://doi.org/10.1093/brain/awy284>
44. van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH et al (2017) Amyotrophic lateral sclerosis. *Lancet* 390:2084–2098. [https://doi.org/10.1016/S0140-6736\(17\)31287-4](https://doi.org/10.1016/S0140-6736(17)31287-4)
45. Evans CS, Holzbaur ELF (2018) Autophagy and mitophagy in ALS. *Neurobiol Dis*. <https://doi.org/10.1016/j.nbd.2018.07.005>
46. Fahrenkrog B, Harel A (2018) Perturbations in traffic: aberrant nucleocytoplasmic transport at the heart of neurodegeneration. *Cells* 7(12):232. <https://doi.org/10.3390/cells7120232>
47. Farg MA, Sundaramoorthy V, Sultana JM, Yang S, Atkinson RAK, Levina V et al (2014) C9ORF72, implicated in amyotrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking. *Hum Mol Genet* 23:3579–3595. <https://doi.org/10.1093/hmg/ddu068>
48. Ferguson CJ, Lenk GM, Meisler MH (2009) Defective autophagy in neurons and astrocytes from mice deficient in PI(3,5)P2. *Hum Mol Genet* 18:4868–4878. <https://doi.org/10.1093/hmg/ddp460>
49. Fiesel FC, Voigt A, Weber SS, Van Den Haute C, Waldenmaier A, Görner K et al (2010) Knockdown of transactive response DNA-binding protein (TDP-43) downregulates histone deacetylase 6. *EMBO J* 29:209–221. <https://doi.org/10.1038/emboj.2009.324>
50. Fratta P, Mizielinska S, Nicoll AJ, Zloh M, Fisher EMC, Parkinson G et al (2012) C9orf72 hexanucleotide repeat associated with amyotrophic lateral sclerosis and frontotemporal dementia forms RNA G-quadruplexes. *Sci Rep* 2:1016. <https://doi.org/10.1038/srep01016>
51. Freibaum BD, Chitta RK, High AA, Taylor JP (2010) Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. *J Proteome Res* 9:1104–1120. <https://doi.org/10.1021/pr901076y>
52. Freibaum BD, Taylor JP (2017) The role of dipeptide repeats in C9ORF72-related ALS-FTD. *Front Mol Neurosci*. <https://doi.org/10.3389/fnmol.2017.00035>
53. Frick P, Sellier C, Mackenzie IRA, Cheng C-Y, Tahraoui-bories J, Martinat C et al (2018) Novel antibodies reveal presynaptic localization of C9orf72 protein and reduced protein levels in C9orf72 mutation carriers. *Acta Neuropathol Commun* 6:1–17. <https://doi.org/10.1186/s40478-018-0579-0>
54. Friedman JR, Webster BM, Mastronarde DN, Verhey KJ, Voeltz GK (2010) ER sliding dynamics and ER-mitochondrial contacts occur on acetylated microtubules. *J Cell Biol* 190:363–375. <https://doi.org/10.1083/jcb.200911024>
55. Fujita Y, Mizuno Y, Takatama M, Okamoto K (2008) Anterior horn cells with abnormal TDP-43 immunoreactivities show fragmentation of the Golgi apparatus in ALS. *J Neurol Sci* 269:30–34. <https://doi.org/10.1016/j.jns.2007.12.016>
56. Fujita Y, Okamoto K, Sakurai A, Gonatas NK, Hirano A (2000) Fragmentation of the Golgi apparatus of the anterior horn cells in patients with familial amyotrophic lateral sclerosis with SOD1 mutations and posterior column involvement. *J Neurol Sci* 174:137–140. [https://doi.org/10.1016/S0022-510X\(00\)00265-3](https://doi.org/10.1016/S0022-510X(00)00265-3)
57. Galea G, Simpson JC (2015) High-content analysis of Rab protein function at the ER-Golgi interface. *Bioarchitecture* 5:44–53. <https://doi.org/10.1080/19490992.2015.1102826>
58. Gendron TF, Bieniek KF, Zhang YJ, Jansen-West K, Ash PEA, Caulfield T et al (2013) Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. *Acta Neuropathol* 126:829–844. <https://doi.org/10.1007/s00401-013-1192-8>
59. Gibbs KL, Kalmar B, Rhymes ER, Fellows AD, Ahmed M, Whiting P et al (2018) Inhibiting p38 MAPK alpha rescues axonal retrograde transport defects in a mouse model of ALS article. *Cell Death Dis* 9:596. <https://doi.org/10.1038/s41419-018-0624-8>
60. Gijssels I, Van Mossevelde S, Van Der Zee J, Sieben A, Philtjens S, Heeman B et al (2015) Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort. *Neurology* 85:2116–2125. <https://doi.org/10.1212/WNL.0000000000002220>
61. Glick D, Barth S, Macleod KF (2010) Autophagy: cellular and molecular mechanisms. *J Pathol* 221:3–12. <https://doi.org/10.1002/path.2697>. Autophagy
62. Gonatas NK, Stieber A, Gonatas JO (2006) Fragmentation of the Golgi apparatus in neurodegenerative diseases and cell death. *J Neurol Sci* 246:21–30. <https://doi.org/10.1016/j.jns.2006.01.019>
63. Gros-Louis F, Larivière R, Gowing G, Laurent S, Camu W, Bouchard JP et al (2004) A frameshift deletion in peripherin gene associated with amyotrophic lateral sclerosis. *J Biol Chem* 279:45951–45956. <https://doi.org/10.1074/jbc.M408139200>
64. Gu F, Crump CM, Thomas G (2001) Trans-Golgi network sorting. *Cell Mol Life Sci* 58:1067–1084

65. Guinto CO, Diarra S, Diallo SSH, Cissé L, Coulibaly T, Diallo SSH et al (2017) A novel mutation in KIF5A in a Malian family with spastic paraplegia and sensory loss. *Ann Clin Transl Neurol* 4:272–275. <https://doi.org/10.1002/actn.3.402>
66. Guo W, Naujock M, Fumagalli L, Vandoorne T, Baatsen P, Boon R et al (2017) HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. *Nat Commun* 8:861. <https://doi.org/10.1038/s41467-017-00911-y>
67. Harrington AW, Ginty DD (2013) Long-distance retrograde neurotrophic factor signalling in neurons. *Nat Rev Neurosci* 14:177–187. <https://doi.org/10.1038/nrn3253>
68. Heffernan LF, Simpson JC (2014) The trials and tubule-ations of Rab6 involvement in Golgi-to-ER retrograde transport. *Biochem Soc Trans* 42:1453–1459. <https://doi.org/10.1042/BST20140178>
69. Heo JM, Ordureau A, Paulo JA, Rinehart J, Harper JW (2015) The PINK1-PARKIN mitochondrial ubiquitylation pathway drives a program of OPTN/NDP52 recruitment and TBK1 activation to promote mitophagy. *Mol Cell* 60:7–20. <https://doi.org/10.1016/j.molcel.2015.08.016>
70. Hiji Masanori M, Takahashi T, Fukuba H, Yamashita H, Kohriyama T, Matsumoto M (2008) White matter lesions in the brain with frontotemporal lobar degeneration with motor neuron disease: TDP-43-immunopositive inclusions co-localize with p62, but not ubiquitin. *Acta Neuropathol*. <https://doi.org/10.1007/s00401-008-0402-2>
71. Hirokawa N, Niwa S, Tanaka Y (2010) Molecular motors in neurons: transport mechanisms and roles in brain function, development, and disease. *Neuron* 68:610–638
72. Hoell JI, Larsson E, Runge S, Nusbaum JD, Duggimpudi S, Farazi TA et al (2011) RNA targets of wild-type and mutant FET family proteins. *Nat Struct Mol Biol* 18:1428–1431. <https://doi.org/10.1038/nsmb.2163>
73. Huber LA, Pimplikar S, Parton RG, Virta H, Zerial M, Simons K (1993) Rab8, a small GTPase involved in vesicular traffic between the TGN and the basolateral plasma membrane. *J Cell Biol* 123:35–45. <https://doi.org/10.1083/jcb.123.1.35>
74. Hutagalung AH, Novick PJ (2011) Role of Rab GTPases in membrane traffic and cell physiology. *Physiol Rev* 91:119–149. <https://doi.org/10.1152/physrev.00059.2009>
75. Ikenaka K, Kawai K, Katsuno M, Huang Z, Jiang YM, Iguchi Y et al (2013) dnc-1/dynactin 1 knockdown disrupts transport of autophagosomes and induces motor neuron degeneration. *PLoS One*. <https://doi.org/10.1371/journal.pone.0054511>
76. Ishiura H, Tsuji S (2015) Epidemiology and molecular mechanism of frontotemporal lobar degeneration/amyotrophic lateral sclerosis with repeat expansion mutation in C9orf72. *J Neurogenet* 29:85–94. <https://doi.org/10.3109/01677063.2015.1085980>
77. Iyer S, Subramanian V, Acharya KR (2018) C9orf72, a protein associated with amyotrophic lateral sclerosis (ALS) is a guanine nucleotide exchange factor. *PeerJ*. <https://doi.org/10.7717/peerj.5815>
78. Jin N, Chow CY, Liu L, Zolov SN, Bronson R, Davison M et al (2008) VAC14 nucleates a protein complex essential for the acute interconversion of PI3P and PI(3,5)P2 in yeast and mouse. *EMBO J* 27:3221–3234. <https://doi.org/10.1038/emboj.2008.248>
79. Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, Trojanowski JQ et al (2010) Exome sequencing reveals VCP mutations as a cause of familial ALS. *Neuron*. <https://doi.org/10.1016/j.neuron.2010.11.036>
80. Kaji S, Kawarai T, Miyamoto R, Nodera H, Pedace L, Orlacchio A et al (2016) Late-onset spastic paraplegia type 10 (SPG10) family presenting with bulbar symptoms and fasciculations mimicking amyotrophic lateral sclerosis. *J Neurol Sci* 364:45–49. <https://doi.org/10.1016/j.jns.2016.03.001>
81. Kawaguchi et al (2003) The deacetylase HDAC6 regulates aggregate formation and cell viability in response to misfolded protein stress. *Cell* 115(6):727–738
82. Kawahara Y, Mieda-Sato A (2012) TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. *Proc Natl Acad Sci* 109:3347–3352. <https://doi.org/10.1073/pnas.1112427109>
83. Khalil B, Morderer D, Price PL, Liu F, Rossoll W (2018) mRNP assembly, axonal transport, and local translation in neurodegenerative diseases. *Brain Res*. <https://doi.org/10.1016/j.brainres.2018.02.018>
84. Kieran D, Hafezparast M, Bohnert S, Dick JRT, Martin J, Schiavo G et al (2005) A mutation in dynein rescues axonal transport defects and extends the life span of ALS mice. *J Cell Biol*. <https://doi.org/10.1083/jcb.200501085>
85. Kim HJ, Taylor JP (2017) Lost in transportation: nucleocytoplasmic transport defects in ALS and other neurodegenerative diseases. *Neuron* 96:285–297
86. Kim SH, Shanware NP, Bowler MJ, Tibbetts RS (2010) Amyotrophic lateral sclerosis-associated proteins TDP-43 and FUS/TLS function in a common biochemical complex to co-regulate HDAC6 mRNA. *J Biol Chem* 285:34097–34105. <https://doi.org/10.1074/jbc.M110.154831>
87. King SM (2012) Integrated control of axonemal dynein AAA+ motors. *J Struct Biol* 179(2):222–228
88. Kinoshita Y, Ito H, Hirano A, Fujita K, Wate R, Nakamura M et al (2009) Nuclear contour irregularity and abnormal transporter protein distribution in anterior horn cells in amyotrophic lateral sclerosis. *J Neuropathol Exp Neurol*. <https://doi.org/10.1097/nen.0b013e3181bc3bec>
89. Koppers M, Blokhuis AM, Westeneng HJ, Terpstra ML, Zundel CAC, Vieira De Sá R et al (2015) C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits. *Ann Neurol* 78:426–438. <https://doi.org/10.1002/ana.24453>
90. Kornblum HI, Raymon HK, Morrison RS, Cavanaugh KP, Bradshaw RA, Leslie FM (1990) Epidermal growth factor and basic fibroblast growth factor: effects on an overlapping population of neocortical neurons in vitro. *Brain Res* 535:255–263. [https://doi.org/10.1016/0006-8993\(90\)91608-J](https://doi.org/10.1016/0006-8993(90)91608-J)
91. Kuijpers M, Lou YuK, Teuling E, Akhmanova A, Jaarsma D, Hoogenraad CC (2013) The ALS8 protein VAPB interacts with the ER-Golgi recycling protein YIF1A and regulates membrane delivery into dendrites. *EMBO J* 32:2056–2072. <https://doi.org/10.1038/emboj.2013.131>
92. Kunita R, Otomo A, Mizumura H, Suzuki K, Showguchi-Miyata J, Yanagisawa Y et al (2004) Homo-oligomerization of ALS2 through its unique carboxyl-terminal regions is essential for the ALS2-associated Rab5 guanine nucleotide exchange activity and its regulatory function on endosome trafficking. *J Biol Chem* 279:38626–38635. <https://doi.org/10.1074/jbc.M406120200>
93. Lagier-Tourenne C, Polymenidou M, Cleveland DW (2010) TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. *Hum Mol Genet* 19(R1):R46–R64
94. Lai C, Xie C, Shim H, Chandran J, Howell BW, Cai H (2009) Regulation of endosomal motility and degradation by amyotrophic lateral sclerosis 2/alsin. *Mol Brain* 2:23. <https://doi.org/10.1186/1756-6606-2-23>
95. Lai S-L, Abramzon Y, Schymick JC, Stephan DA, Dunckley T, Dillman A et al (2011) FUS mutations in sporadic amyotrophic lateral sclerosis. *Neurobiol Aging* 32:550.e1–550.e4. <https://doi.org/10.1016/j.neurobiolaging.2009.12.020>
96. Lanson NA, Maltare A, King H, Smith R, Kim JH, Taylor JP et al (2013) Rethinking ALS: the FUS about TDP-43. *Cell* 56:1001–1004. <https://doi.org/10.1016/j.mcn.2013.03.006>
97. Lazarou M, Sliter DA, Kane LA, Sarraf SA, Wang C, Burman JL et al (2015) The ubiquitin kinase PINK1 recruits autophagy

- receptors to induce mitophagy. *Nature* 524:309–314. <https://doi.org/10.1038/nature14893>
98. Lee JK, Shin JH, Lee JE, Choi EJ (2015) Role of autophagy in the pathogenesis of amyotrophic lateral sclerosis. *Biochim Biophys Acta Mol Basis Dis* 1852(11):2517–2524. <https://doi.org/10.1016/j.bbadis.2015.08.005>
 99. Lev S, Ben Halevy D, Peretti D, Dahan N (2008) The VAP protein family: from cellular functions to motor neuron disease. *Trends Cell Biol* 18:282–290
 100. Levine TP, Daniels RD, Gatta AT, Wong LH, Hayes MJ (2013) The product of C9orf72, a gene strongly implicated in neurodegeneration, is structurally related to DENN Rab-GEFs. *Bioinformatics* 29:499–503. <https://doi.org/10.1093/bioinformatics/bts725>
 101. Levy JR, Sumner CJ, Caviston JP, Tokito MK, Ranganathan S, Ligon LA et al (2006) A motor neuron disease-associated mutation in p150Glued perturbs dynactin function and induces protein aggregation. *J Cell Biol* 172:733–745. <https://doi.org/10.1083/jcb.200511068>
 102. Ling S-C, Albuquerque CP, Han JS, Lagier-Tourenne C, Tokunaga S, Zhou H et al (2010) ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. *Proc Natl Acad Sci* 107:13318–13323. <https://doi.org/10.1073/pnas.1008227107>
 103. Ling SC, Polymenidou M, Cleveland DW (2013) Converging mechanisms in als and FTD: disrupted RNA and protein homeostasis. *Neuron* 79:416–438
 104. Liu S, Storrie B (2012) Are Rab proteins the link between Golgi organization and membrane trafficking? *Cell Mol Life Sci* 69(24):4093–4106. <https://doi.org/10.1007/s00018-012-1021-6>
 105. Liu T-T, Gomez TS, Sackey BK, Billadeau DD, Burd CG (2012) Rab GTPase regulation of retromer-mediated cargo export during endosome maturation. *Mol Biol Cell* 23:2505–2515. <https://doi.org/10.1091/mbc.E11-11-0915>
 106. Liu Y, Pattamatta A, Zu T, Reid T, Bardhi O, Borchelt DR et al (2016) C9orf72 BAC mouse model with motor deficits and neurodegenerative features of ALS/FTD. *Neuron*. <https://doi.org/10.1016/j.neuron.2016.04.005>
 107. Mackenzie IR, Rademakers R, Neumann M (2010) TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. *Lancet Neurol* 9:995–1007. [https://doi.org/10.1016/S1474-4422\(10\)70195-2](https://doi.org/10.1016/S1474-4422(10)70195-2)
 108. Mackenzie IRA, Frick P, Neumann M (2014) The neuropathology associated with repeat expansions in the C9ORF72 gene. *Acta Neuropathol* 127:347–357
 109. Marat AL, Haucke V (2016) Phosphatidylinositol 3-phosphates—at the interface between cell signalling and membrane traffic. *EMBO J* 35:561–579. <https://doi.org/10.15252/embj.201593564>
 110. Markgraf DF, Peplowska K, Ungermann C (2007) Rab cascades and tethering factors in the endomembrane system. *FEBS Lett* 581:2125–2130
 111. De Matteis MA, Luini A (2008) Exiting the Golgi complex. *Nat Rev Mol Cell Biol* 9:273–284
 112. Miskiewicz K, Jose LE, Yeshaw WM, Valadas JS, Swerts J, Munck S et al (2014) HDAC6 is a bruchpilot deacetylase that facilitates neurotransmitter release. *Cell Rep* 8:94–102. <https://doi.org/10.1016/j.celrep.2014.05.051>
 113. Mitne-Neto M, Machado-Costa M, Marchetto MCN, Bengtson MH, Joazeiro CA, Tsuda H et al (2011) Downregulation of VAPB expression in motor neurons derived from induced pluripotent stem cells of ALS8 patients. *Hum Mol Genet* 20:3642–3652. <https://doi.org/10.1093/hmg/ddr284>
 114. Mizuno Y, Fujita Y, Takatama M, Okamoto K (2011) Peripheral partially localizes in Bunina bodies in amyotrophic lateral sclerosis. *J Neurol Sci* 302:14–18. <https://doi.org/10.1016/j.jns.2010.12.023>
 115. Mizusawa H, Matsumoto S, Yen SH, Hirano A, Rojas-Corona RR, Donnenfeld H (1989) Focal accumulation of phosphorylated neurofilaments within anterior horn cell in familial amyotrophic lateral sclerosis. *Acta Neuropathol* 79:37–43. <https://doi.org/10.1007/BF00308955>
 116. Mockrin SC, Korn ED (1980) Acanthamoeba profilin interacts with G-actin to increase the rate of exchange of actin-bound adenosine 5'-triphosphate. *Biochemistry*. <https://doi.org/10.1021/bi00564a033>
 117. Morfini GA, Bosco DA, Brown H, Gatto R, Kaminska A et al (2013) Inhibition of fast axonal transport by pathogenic SOD1 involves activation of p38 MAP kinase. *PLoS One* 8:e65235. <https://doi.org/10.1371/journal.pone.0065235>
 118. Mori K, Arzberger T, Grässer FA, Gijssels I, May S, Rentzsch K et al (2013) Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. *Acta Neuropathol* 126:881–893. <https://doi.org/10.1007/s00401-013-1189-3>
 119. Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kremmer E et al (2013) The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTL/ALS. *Science* (80-) 339:1335–1338. <https://doi.org/10.1126/science.1232927>
 120. Münch C, Meyer R, Linke P, Meyer T, Ludolph AC, Haas J et al (2007) The p150 subunit of dynactin (DCTN1) gene in multiple sclerosis. *Acta Neurol Scand* 116:231–234. <https://doi.org/10.1111/j.1600-0404.2007.00884.x>
 121. Munoz DG, Greene C, Perl DP, Selkoe DJ (1988) Accumulation of phosphorylated neurofilaments in anterior horn motoneurons of amyotrophic lateral sclerosis patients. *J Neuropathol Exp Neurol* 47:9–18. <https://doi.org/10.1097/00005072-198801000-00002>
 122. Nagabhushana A, Chalasani ML, Jain N, Radha V, Rangaraj N, Balasubramanian D et al (2010) Regulation of endocytic trafficking of transferrin receptor by optineurin and its impairment by a glaucoma-associated mutant. *BMC Cell Biol*. <https://doi.org/10.1186/1471-2121-11-4>
 123. Nakajima K, Yin X, Takei Y, Seog DH, Homma N, Hirokawa N (2012) Molecular motor KIF5A is essential for GABAA receptor transport, and KIF5A deletion causes epilepsy. *Neuron*. <https://doi.org/10.1016/j.neuron.2012.10.012>
 124. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT et al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science* (80-) 314:130–133. <https://doi.org/10.1126/science.1134108>
 125. Neumann M, Valori CF, Ansorge O, Kretzschmar HA, Munoz DG, Kusaka H et al (2012) Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTL/ALS and is absent in FUS inclusions in ALS with FUS mutations. *Acta Neuropathol*. <https://doi.org/10.1007/s00401-012-1020-6>
 126. Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R et al (2018) Genome-wide analyses identify KIF5A as a novel ALS gene. *Neuron* 97:1268–1283.e6. <https://doi.org/10.1016/j.neuron.2018.02.027>
 127. Nishimura AL, Mitne-Neto M, Silva HCA, Richieri-Costa A, Middleton S, Cascio D et al (2004) A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. *Am J Hum Genet* 75:822–831. <https://doi.org/10.1086/425287>
 128. Nishimura AL, Upunski V, Troakes C, Kathe C, Fratta P, Howell M et al (2010) Nuclear import impairment causes cytoplasmic trans-activation response DNA-binding protein accumulation and is associated with frontotemporal lobar degeneration. *Brain*. <https://doi.org/10.1093/brain/awq111>

129. Oakes JA, Davies MC, Collins MO (2017) TBK1: a new player in ALS linking autophagy and neuroinflammation. *Mol Brain* 10:1–10. <https://doi.org/10.1186/s13041-017-0287-x>
130. Odorizzi G, Babst M, Emr SD (1998) Fab1p PtdIns(3)P 5-kinase function essential for protein sorting in the multivesicular body. *Cell* 95:847–858. [https://doi.org/10.1016/S0092-8674\(00\)81707-9](https://doi.org/10.1016/S0092-8674(00)81707-9)
131. Osmanovic A, Rangnau I, Kosfeld A, Abdulla S, Janssen C, Auber B et al (2017) FIG 4 variants in central European patients with amyotrophic lateral sclerosis: a whole-exome and targeted sequencing study. *Eur J Hum Genet* 25:324–331. <https://doi.org/10.1038/ejhg.2016.186>
132. Otomo A, Hadano S, Okada T, Mizumura H, Kunita R, Nishijima H et al (2003) ALS2, a novel guanine nucleotide exchange factor for the small GTPase Rab5, is implicated in endosomal dynamics. *Hum Mol Genet* 12:1671–1687
133. Otomo A, Pan L, Hadano S (2012) Dysregulation of the autophagy-endolysosomal system in amyotrophic lateral sclerosis and related motor neuron diseases. *Neurol Res Int* 2012:498428. <https://doi.org/10.1155/2012/498428>
134. Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H et al (2007) p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. *J Biol Chem* 282(33):24131–24145
135. Papiiani G, Ruggiano A, Fossati M, Raimondi A, Bertoni G, Francolini M et al (2012) Restructured endoplasmic reticulum generated by mutant amyotrophic lateral sclerosis-linked VAPB is cleared by the proteasome. *J Cell Sci* 125:3601–3611. <https://doi.org/10.1242/jcs.102137>
136. Pearson JP, Williams NM, Majounie E, Waite A, Stott J, Newsway V et al (2011) Familial frontotemporal dementia with amyotrophic lateral sclerosis and a shared haplotype on chromosome 9p. *J Neurol* 258:647–655. <https://doi.org/10.1007/s00415-010-5815-x>
137. Peretti D, Dahan N, Shimoni E, Hirschberg K, Lev S (2008) Coordinated lipid transfer between the endoplasmic reticulum and the golgi complex requires the VAP proteins and is essential for Golgi-mediated transport. *Mol Biol Cell* 19:3871–3884. <https://doi.org/10.1091/mbc.E08-05-0498>
138. Prahlad V, Helfand BT, Langford GM, Vale RD, Goldman RD (2000) Fast transport of neurofilament protein along microtubules in squid axoplasm. *J Cell Sci* 113(Pt 2):3939–3946
139. Ramesh N, Pandey UB (2017) Autophagy dysregulation in ALS: when protein aggregates get out of hand. *Front Mol Neurosci*. <https://doi.org/10.3389/fnmol.2017.00263>
140. Randall TS, Moores C, Stephenson FA (2013) Delineation of the TRAK binding regions of the kinesin-1 motor proteins. *FEBS Lett*. <https://doi.org/10.1016/j.febslet.2013.09.049>
141. Reed NA, Cai D, Blasius TL, Jih GT, Meyhofer E, Gaertig J et al (2006) Microtubule acetylation promotes kinesin-1 binding and transport. *Curr Biol* 16:2166–2172. <https://doi.org/10.1016/j.cub.2006.09.014>
142. Renton AE, Chiò A, Traynor BJ (2014) State of play in amyotrophic lateral sclerosis genetics. *Nat Neurosci* 17:17–23
143. Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, Gibbs JR et al (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. *Neuron* 72:257–268. <https://doi.org/10.1016/j.neuron.2011.09.010>
144. Robberecht W, Philips T (2013) The changing scene of amyotrophic lateral sclerosis. *Nat Rev Neurosci* 14:248–264
145. Rothman JE, Wieland FT (1996) Protein sorting by transport vesicles. *Science* (80-) 272:227–234. <https://doi.org/10.1126/science.272.5259.227>
146. Rudge SA (2003) Vacuole size control: regulation of PtdIns(3,5) p2 levels by the vacuole-associated Vac14-Fig4 complex, a PtdIns(3,5)P2-specific phosphatase. *Mol Biol Cell* 15:24–36. <https://doi.org/10.1091/mbc.E03-05-0297>
147. Ryu HH, Jun MH, Min KJ, Jang DJ, Lee YS, Kim HK et al (2014) Autophagy regulates amyotrophic lateral sclerosis-linked fused in sarcoma-positive stress granules in neurons. *Neurobiol Aging*. <https://doi.org/10.1016/j.neurobiolaging.2014.07.026>
148. Sainath R, Gallo G (2015) The dynein inhibitor Ciliobrevin D inhibits the bidirectional transport of organelles along sensory axons and impairs NGF-mediated regulation of growth cones and axon branches. *Dev Neurobiol* 75:757–777. <https://doi.org/10.1002/dneu.22246>
149. Sama RRRK, Fallini C, Gatto R, McKeon JE, Song Y, Rotunno MS et al (2017) ALS-linked FUS exerts a gain of toxic function involving aberrant p38 MAPK activation. *Sci Rep* 7:115. <https://doi.org/10.1038/s41598-017-00091-1>
150. Schwenk BM, Hartmann H, Serdaroglu A, Schludi MH, Hornburg D, Meissner F et al (2016) TDP-43 loss of function inhibits endosomal trafficking and alters trophic signaling in neurons. *EMBO J* 35:2350–2370. <https://doi.org/10.15252/embj.201694221>
151. Scotter EL, Chen HJ, Shaw CE (2015) TDP-43 proteinopathy and ALS: insights into disease mechanisms and therapeutic targets. *Neurotherapeutics* 12(2):352–363. <https://doi.org/10.1007/s13311-015-0338-x>
152. Sellier C, Campanari M, Julie Corbier C, Gaucherot A, Kolb-Cheynel I, Oulad-Abdelghani M et al (2016) Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin-2 to induce motor neuron dysfunction and cell death. *EMBO J* 35:1276–1297. <https://doi.org/10.15252/embj.201593350>
153. Sephton CF, Cenik C, Kucukural A, Dammer EB, Cenik B, Han Y et al (2011) Identification of neuronal RNA targets of TDP-43-containing ribonucleoprotein complexes. *J Biol Chem* 286:1204–1215. <https://doi.org/10.1074/jbc.M110.190884>
154. Settembre C, Fraldi A, Medina DL, Ballabio A (2013) Signals from the lysosome: a control centre for cellular clearance and energy metabolism. *Nat Rev Mol Cell Biol* 14:283–296
155. Shang J, Yamashita T, Nakano Y, Morihara R, Li X, Feng T et al (2017) Aberrant distributions of nuclear pore complex proteins in ALS mice and ALS patients. *Neuroscience*. <https://doi.org/10.1016/j.neuroscience.2017.03.024>
156. Shi KY, Mori E, Nizami ZF, Lin Y, Kato M, Xiang S et al (2017) Toxic PR_n poly-dipeptides encoded by the C9orf72 repeat expansion block nuclear import and export. *Proc Natl Acad Sci*. <https://doi.org/10.1073/pnas.1620293114>
157. Sivadasan R, Hornburg D, Drepper C, Frank N, Jablonka S, Hansel A et al (2016) C9ORF72 interaction with cofilin modulates actin dynamics in motor neurons. *Nat Neurosci* 19:1610–1618. <https://doi.org/10.1038/nn.4407>
158. Smith BN, Ticozzi N, Fallini C, Gkazi AS, Topp S, Kenna KP et al (2014) Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS. *Neuron* 84:324–331. <https://doi.org/10.1016/j.neuron.2014.09.027>
159. Soo KY, Halloran M, Sundaramoorthy V, Parakh S, Toth RP, Southam KA et al (2015) Rab1-dependent ER–Golgi transport dysfunction is a common pathogenic mechanism in SOD1, TDP-43 and FUS-associated ALS. *Acta Neuropathol* 130:679–697. <https://doi.org/10.1007/s00401-015-1468-2>
160. Soussan L, Burakov D, Daniels MP, Toister-Achituv M, Porat A, Yarden Y et al (1999) ERG30, a VAP-33-related protein, functions in protein transport mediated by COPI vesicles. *J Cell Biol* 146:301–311. <https://doi.org/10.1083/jcb.146.2.301>
161. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B et al (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. *Science* 319:1668–1672. <https://doi.org/10.1126/science.1154584>

162. Stenmark H (2009) Rab GTPases as coordinators of vesicle traffic. *Nat Rev Mol Cell Biol* 10:513–525
163. Stoica R, Paillusson S, Gomez-Suaga P, Mitchell JC, Lau DH, Gray EH et al (2016) ALS/FTD associated FUS activates GSK3 β to disrupt the VAPB–PTPIP51 interaction and ER-mitochondria associations. *EMBO Rep* 13:e201541726. <https://doi.org/10.15252/embr.201541726>
164. Stoica R, De Vos KJ, Paillusson S, Mueller S, Sancho RM, Lau KF et al (2014) ER-mitochondria associations are regulated by the VAPB–PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43. *Nat Commun* 5:3996. <https://doi.org/10.1038/ncomms4996>
165. Sundaramoorthy V, Walker AK, Yerbury J, Soo KY, Farg MA, Hoang V et al (2013) Extracellular wild-type and mutant SOD1 induces ER-Golgi pathology characteristic of amyotrophic lateral sclerosis in neuronal cells. *Cell Mol Life Sci* 70:4181–4195. <https://doi.org/10.1007/s00018-013-1385-2>
166. Sunil N, Lee S, Shea TB (2012) Interference with kinesin-based anterograde neurofilament axonal transport increases neurofilament-neurofilament bundling. *Cytoskeleton* 69:371–379. <https://doi.org/10.1002/cm.21030>
167. Taes I, Timmers M, Hersmus N, Bento-Abreu A, Van Den Bosch L, Van Damme P et al (2013) Hdac6 deletion delays disease progression in the sod1g93a mouse model of als. *Hum Mol Genet* 22:1783–1790. <https://doi.org/10.1093/hmg/ddt028>
168. Takeuchi H, Mizuno T, Zhang G, Wang J, Kawanokuchi J, Kuno R et al (2005) Neuritic beading induced by activated microglia is an early feature of neuronal dysfunction toward neuronal death by inhibition of mitochondrial respiration and axonal transport. *J Biol Chem*. <https://doi.org/10.1074/jbc.M413863200>
169. Takeuchi R, Toyoshima Y, Tada M, Shiga A, Tanaka H, Shimohata M et al (2013) Transportin 1 accumulates in FUS inclusions in adult-onset ALS without FUS mutation. *Neuropathol. Appl. Neurobiol*
170. Taylor JP, Brown RH, Cleveland DW (2016) Decoding ALS: from genes to mechanism. *Nature* 539:197–206
171. Teuling E, Ahmed S, Haasdijk E, Demmers J, Steinmetz MO, Akhmanova A et al (2007) Motor neuron disease-associated mutant vesicle-associated membrane protein-associated protein (VAP) B recruits wild-type VAPs into endoplasmic reticulum-derived tubular aggregates. *J Neurosci* 27:9801–9815. <https://doi.org/10.1523/JNEUROSCI.2661-07.2007>
172. Tilney LG, Bonder EM, Coluccio LM, Mooseker MS (1983) Actin from Thyone sperm assembles on only one end of an actin filament: a behavior regulated by profilin. *J Cell Biol*. <https://doi.org/10.1083/jcb.97.1.112>
173. del Toro D, Alberch J, Lazaro-Dieguez F, Martin-Ibanez R, Xifro X, Egea G et al (2009) Mutant huntingtin impairs post-Golgi trafficking to lysosomes by delocalizing optineurin/Rab8 complex from the Golgi apparatus. *Mol Biol Cell* 20:1478–1492. <https://doi.org/10.1091/mbc.E08-07-0726>
174. Tumbarello DA, Waxse BJ, Arden SD, Bright NA, Kendrick-Jones J, Buss F (2012) Autophagy receptors link myosin VI to autophagosomes to mediate Tom1-dependent autophagosome maturation and fusion with the lysosome. *Nat Cell Biol* 14:1024–1035. <https://doi.org/10.1038/ncb2589>
175. Ugolino J, Ji YJ, Conchina K, Chu J, Nirujogi RS, Pandey A et al (2016) Loss of C9orf72 enhances autophagic activity via deregulated mTOR and TFEB signaling. *PLoS Genet* 12:e1006443. <https://doi.org/10.1371/journal.pgen.1006443>
176. Utskarpen A, Slagsvold HH, Iversen TG, Wälchli S, Sandvig K (2006) Transport of ricin from endosomes to the golgi apparatus is regulated by Rab6A and Rab6A'. *Traffic* 7:663–672. <https://doi.org/10.1111/j.1600-0854.2006.00418.x>
177. Vance C, Al-Chalabi A, Ruddy D, Smith BN, Hu X, Sreedharan J et al (2006) Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2–21.3. *Brain* 129:868–876. <https://doi.org/10.1093/brain/awl030>
178. Vanhaesebroeck B, Vogt PK, Rommel C (2010) PI3K: from the bench to the clinic and back. *Curr Top Microbiol Immunol* 347:1–19
179. De Vos KJ, Hafezparast M (2017) Neurobiology of axonal transport defects in motor neuron diseases: opportunities for translational research? *Neurobiol Dis* 105:283–299. <https://doi.org/10.1016/j.nbd.2017.02.004>
180. Wang X, Zhou S, Ding X, Ma M, Zhang J, Zhou Y, Wu E, Teng J (2015) Activation of ER stress and autophagy induced by TDP-43 A315T as pathogenic mechanism and the corresponding histological changes in skin as potential biomarker for ALS with the mutation. *Int J Biol Sci*. <https://doi.org/10.7150/ijbs.12657>
181. Webster BM, Colombi P, Jäger J, Patrick Lusk C (2014) Surveillance of nuclear pore complex assembly by ESCRT-III/Vps4. *Cell*. <https://doi.org/10.1016/j.cell.2014.09.012>
182. Webster CP, Smith EF, Bauer CS, Moller A, Hautbergue GM, Ferraiuolo L et al (2016) The C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate initiation of autophagy. *EMBO J* 35:1656–1676. <https://doi.org/10.15252/emboj.201694401>
183. Whitley P, Reaves BJ, Hashimoto M, Riley AM, Potter BVL, Holman GD (2003) Identification of mammalian Vps24p as an effector of phosphatidylinositol 3,5-bisphosphate-dependent endosome compartmentalization. *J Biol Chem* 278:38786–38795. <https://doi.org/10.1074/jbc.M306864200>
184. Wild P, Farhan H, McEwan DG, Wagner S, Rogov VV, Brady NR et al (2011) Phosphorylation of the autophagy receptor optineurin restricts Salmonella growth. *Science* (80-) 333:228–233. <https://doi.org/10.1126/science.1205405>
185. Williams KL, Warrich ST, Yang S, Solski JA, Fernando R, Rouleau GA et al (2012) UBQLN2/ubiquilin 2 mutation and pathology in familial amyotrophic lateral sclerosis. *Neurobiol Aging*. <https://doi.org/10.1016/j.neurobiolaging.2012.05.008>
186. Williamson TL, Bruijn LI, Zhu Q, Anderson KL, Anderson SD, Julien J-P et al (1998) Absence of neurofilaments reduces the selective vulnerability of motor neurons and slows disease caused by a familial amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutant. *Proc Natl Acad Sci* 95:9631–9636. <https://doi.org/10.1073/pnas.95.16.9631>
187. Woerner AC, Frottin F, Hornburg D, Feng LR, Meissner F, Patra M et al (2016) Cytoplasmic protein aggregates interfere with nucleocytoplasmic transport of protein and RNA. *Science* (80-). <https://doi.org/10.1126/science.aad2033>
188. Wong YC, Holzbaur ELF (2014) Optineurin is an autophagy receptor for damaged mitochondria in parkin-mediated mitophagy that is disrupted by an ALS-linked mutation. *Proc Natl Acad Sci* 111:E4439–E4448. <https://doi.org/10.1073/pnas.1405752111>
189. Wu C-H, Fallini C, Ticozzi N, Keagle PJ, Sapp PC, Piotrowska K et al (2012) Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. *Nature* 488:499–503. <https://doi.org/10.1038/nature11280>
190. Xi Z, Zinman L, Moreno D, Schymick J, Liang Y, Sato C et al (2013) Hypermethylation of the CpG island near the G4C2 repeat in ALS with a C9orf72 expansion. *Am J Hum Genet* 92:981–989. <https://doi.org/10.1016/j.ajhg.2013.04.017>
191. Xia CH, Roberts EA, Her LS, Liu X, Williams DS, Cleveland DW et al (2003) Abnormal neurofilament transport caused by targeted disruption of neuronal kinesin heavy chain KIF5A. *J Cell Biol* 161:55–66. <https://doi.org/10.1083/jcb.200301026>
192. Yamanaka K, Vande Velde C, Eymard-Pierre E, Bertini E, Boespflug-Tanguy O, Cleveland DW (2003) Unstable mutants in the peripheral endosomal membrane component ALS2 cause early-onset motor neuron disease. *Proc Natl Acad Sci* 100:16041–16046. <https://doi.org/10.1073/pnas.2635267100>

193. Ye H, Kuruville R, Zweifel LS, Ginty DD (2003) Evidence in support of signaling endosome-based retrograde survival of sympathetic neurons. *Neuron* 39:57–68. [https://doi.org/10.1016/S0896-6273\(03\)00266-6](https://doi.org/10.1016/S0896-6273(03)00266-6)
194. Shi Y, Lin S, Staats KA, Li W-HCY, Hung ST, Hendricks E et al (2018) Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. *Nat Med* 24:313–325
195. Yoshida Y, Suzuki K, Yamamoto A, Sakai N, Bando M, Tanimoto K et al (2008) YIPF5 and YIF1A recycle between the ER and the Golgi apparatus and are involved in the maintenance of the Golgi structure. *Exp Cell Res* 314:3427–3443. <https://doi.org/10.1016/j.yexcr.2008.07.023>
196. Zhang D, Iyer LM, He F, Aravind L (2012) Discovery of novel DENN proteins: implications for the evolution of eukaryotic intracellular membrane structures and human disease. *Front Genet* 3:283. <https://doi.org/10.3389/fgene.2012.00283>
197. Zhang K, Donnelly CJ, Haeusler AR, Grima JC, Machamer JB, Steinwald P et al (2015) The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. *Nature*. <https://doi.org/10.1038/nature14973>
198. Zhang K, Liu Q, Shen D, Tai H, Liu S, Wang Z et al (2018) Mutation analysis of KIF5A in Chinese amyotrophic lateral sclerosis patients. *Neurobiol Aging* 73:229.e1–229.e4. <https://doi.org/10.1016/j.neurobiolaging.2018.08.006>
199. Zhen Y, Stenmark H (2015) Cellular functions of Rab GTPases at a glance. *J Cell Sci* 128:3171–3176. <https://doi.org/10.1242/jcs.166074>
200. Zhu G, Wu CJ, Zhao Y, Ashwell JD (2007) Optineurin negatively regulates TNF α -induced NF- κ B activation by competing with NEMO for ubiquitinated RIP. *Curr Biol* 17:1438–1443. <https://doi.org/10.1016/j.cub.2007.07.041>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.